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Chapter 1: Introduction 
 
1.1 Multiple Sclerosis 
 
Multiple sclerosis (MS) is a chronic immune-mediated inflammatory 
demyelinating disease of the central nervous system (CNS) initially identified 
in 1868 by Jean-Martin Charcot. Morphologically, it is characterized by 
inflammation, demyelination, axonal injury and gliosis [1]. Its name is due at 
the presence of multiple discrete sclerotic plaques in white matter of the brain 
and spinal cord; however, it’s also known as “disseminated sclerosis” or 
“encephalomyelitis disseminata”. Plaques are the most recognized pathologic 
hallmarks of MS and consist in areas of white matter demyelination, often 
inflammatory. From a biological point of view active plaques are 
characterized by massive perivascular spaces infiltration of mononuclear 
cells (T cells, B lymphocytes, plasma cells, macrophages) and soluble 
mediators of the immune system including a broad range of cytokines, 
chemokines, antibodies, complement and other toxic substances. Both the 
myelin sheath and the oligodendrocyte itself are destroyed within plaques, 
following attack by cells of the immune system that react with myelin-related 
epitopes, such as myelin basic protein (MBP) [1]. 
MS represents the major cause of nervous system disability affecting about 
2.5 million people worldwide, with a 2-3:1 female to male ratio. Disease 
onset is usually in the third or fourth decade, but 2% of patients with MS 
present it before age 10 years, and 5% before age 16 years [2]. The estimated 
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incidence of the disease is greatest at the extremes of latitude in both the 
northern and southern hemisphere and it’s of about seven per 100,000 every 
year. Moreover the prevalence is of around 120 per 100,000 and the lifetime 
risk is of one in 400 [2]. 
 
1.1.1 Symptoms and signs of MS 
 
The CNS controls much of the body’s functioning and much of this activity 
passes through the white matter at some point. It is not surprising, therefore, 
that a disease like MS which damages white matter can produce a very wide 
range of symptoms. Symptoms of MS usually appear in episodic acute 
periods of worsening (called relapses, exacerbations, bouts, attacks, or “flare-
ups”), in a gradually progressive deterioration of neurologic function, or in a 
combination of both. The relapses are believed to be the consequences of 
focal inflammatory demyelinating lesions, the histopathological hallmark of 
MS. Relapses are often unpredictable, occurring without warning and without 
obvious inciting factors with a rate rarely above one and a half per year. 
Some attacks, however, are preceded by common triggers: for example 
spring and summer, viral infections (such as the common cold, influenza, or 
gastroenteritis), stress and pregnancy increase the risk of relapse [3]. There 
are no clinical symptoms that are unique to MS, but some are highly 
characteristic of the disease. Some of the major MS symptoms include: 
٠ visual impairment 
٠ motor and sensory deficits 
٠ difficulties with coordination and balance 
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٠ bowel and bladder incontinence 
٠ sexual dysfunction 
٠ cognitive dysfunction 
٠ depression 
٠ severe fatigue 
٠ pain 
However, there are more than 50 symptoms characterizing the intermittent 
episodes of disease relapse, and each one can vary in severity, duration and 
associated disability. MS affects the ability of nerve cells in the brain and 
spinal cord to communicate with each other effectively. Nerve cells 
communicate by sending electrical signals called “action potentials” down 
long fibers called axons, which are contained within an insulating substance 
called myelin (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Conduction of the action potential along a myelinated nerve fiber. (Photo by 
A.D.A.M Medical Illustration Team) 
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In MS, the recurrent immune system’s inflammatory attacks on the white 
matter of the brain and spinal cord damage the myelin. Hence the neurologic 
manifestations of the disease, that arise from the immune-mediated 
demyelination which impairs the neuronal transmission and results in axonal 
degeneration, reflect the functional anatomy of impaired salutatory 
conduction at affected sites [4]. In particular, lesions of the brain stem and 
cerebellar pathways typically disrupt the coordinated movement of the eyes, 
limbs, bulbar musculature, and axial muscles; while spinal cord lesions lead 
to alterations in motor, sensory, and autonomic functions. The prognosis is 
relatively good when sensory or visual symptoms dominate the course of 
multiple sclerosis in adults, and there is complete recovery from individual 
episodes. This pattern is most common in young women. Conversely, motor 
involvement, especially when coordination or balance are disturbed, has a 
less positive prognosis. The outlook is also poor in older men who develop 
the disease. Frequent and prolonged relapses with incomplete recovery at 
onset and a short interval between the initial episode and first relapse are 
adverse prognostic features, but the main determinant of disability is onset of 
the progressive phase [2]. 
 
1.1.2 MS subtypes and diagnostic criteria 
 
In 1996 the United States National Multiple Sclerosis Society standardized 
four clinical MS courses (Fig. 2), named: 
٠ relapsing remitting 
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٠ secondary progressive 
٠ primary progressive 
٠ progressive relapsing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Graphical summary of MS subtype. A. Relapsing-remitting MS (RRMS); B. 
Primary- Progressive MS (PPMS); C. Secondary-Progressive MS (SPMS); D. Progressive-
Relapsing MS (PRMS) [5]. 
 
 
MS subtypes use the past course of the disease in an attempt to predict the 
future course. In fact, clinical course and disease onset of MS are highly 
variable and mostly unpredictable. However, MS subtypes are important not 
only for prognosis but also for therapeutic decisions. 
The most common MS subtype shows a waxing and waning of signs and 
symptoms to produce a “relapsing-remitting” clinical presentation. The 
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disease often begins in early adulthood with intermittent episodes of 
neurological dysfunction. “Relapsing remitting MS” (RRMS) affects ~85% 
of patients and, typically, the illness passes through phases of relapse with 
full recovery, relapse with persistent deficit, and  secondary progression [2]. 
In general within a decade, approximately 50–60% of RRMS patients will 
suffer from “secondary progressive MS” (SPMS), a form that shows less 
inflammation and more neurodegeneration. The progressive phase is 
dominated by diffuse white matter abnormalities, atrophy and cortical 
demyelination but not new gadolinium-enhancing lesions. 
Conversely, about 15% of patients develop a “primary progressive MS” 
(PPMS), a distinct form of MS that it’s not clearly associated with relapses 
and shows neurodegeneration with a relative lack of inflammatory change. 
The onset of PPMS is typically about 10 years later than RRMS but at a 
similar age when the conversion to SPMS occurs [6]. 
A less common form of MS, progressive relapsing MS (PRMS), is 
progressive from the onset but it also presents acute relapses with or without 
full recovery. This MS subtype develops in 5% of diagnosed MS cases [6]. 
Although many persons lead full and rewarding lives, MS can also result in 
longterm disability. In particular in about a quarter of patients, MS never 
affects activities of daily living; conversely, up to 15% become severely 
disabled within a short time. Fixed disability in MS is acquired through two 
distinct mechanisms: incomplete recovery from relapse and disease 
progression. Patients with RRMS accumulate disability from disease onset 
more slowly than those with PPMS [2]. The main clinical measure of 
disability progression and symptom severity is the Expanded Disability 
Status Scale or EDSS. In detail, the EDSS is considered the gold standard for 
assessing the level of physical disability in MS: it’s an ordinal scale with 19 
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disease steps between 0 and 10, that measures impairment or activity 
limitation based on the examination of eight functional systems plus 
ambulation [7]. 
There are several reasons why MS diagnosis is extremely difficult, including 
the fact that: more than 50 symptoms are linked to MS, and each person 
develops symptoms differently; many of the symptoms mimic problems that 
occur with other diseases; there is no blood test for MS yet; symptoms 
usually come and go; many symptoms are vague and hard to quantify, such 
as fatigue, sexual dysfunction, depression and cognitive difficulties. 
Medical organizations have created diagnostic criteria to ease and standardize 
the diagnostic process especially in the first stages of the disease. 
Historically, the Schumacher and Poser criteria were both popular; currently, 
McDonald criteria are regarded as the gold standard for non-invasive MS 
diagnosis. McDonald criteria, that are recommended in the guidelines of the 
International Panel on MS Diagnosis, imply the objective evidence of 
dissemination in time and space of lesions typical of MS and the exclusion of 
other, better explanations for the clinical features [8]. Therefore individuals 
must have a minimum of two attacks, affecting more than one anatomical 
site; but, assuming an initial presentation suggestive of MS, the second lesion 
need not necessarily be clinically express [2]. The most commonly used 
diagnostic tools are neuroimaging, analysis of cerebrospinal fluid and evoked 
potentials. The diagnosis of MS has been revolutionized with the introduction 
of the magnetic resonance imaging (MRI) technology. MRIs use magnetic 
waves to produce images of the brain and spinal cord; at the same time, a 
special contrast material (called gadolinium) reacts to areas of inflammation 
allowing to detect the multiple gadolinium-enhancing lesions, distributed 
throughout the white matter of the CNS. This technology is considered the 
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best test for diagnosing MS, as abnormal lesions appear on MRIs in over 
95% of people with MS. However, 5% of people with MS do not have 
abnormalities that can be detected on an MRI (producing a false negative), 
and some age-related damage looks like MS lesions (producing a false 
positive). Hence, MRI is essential but not sufficient for a correct MS 
diagnosis, requiring to be integrated with clinical and other paraclinical 
diagnostic methods. Studies of surrogate markers of disease activity revealed 
another diagnostic important immunopathological feature in MS, that is the 
presence of oligoclonal bands (OCBs) in cerebrospinal fluid (CSF). The CSF 
can be considered a ‘window to the brain’; moreover, OCBs that arise from 
the continuous intrathecal synthesis of immunoglobulins (predominantly 
oligoclonal IgG’s) are present in more than 90% of patients with MS. Testing 
of CSF obtained from a lumbar puncture can provide  evidence of chronic 
inflammation of the central nervous system. Currently, the presence of these 
bands on isoelectric focusing (IEF) gels is one of the reliable laboratory tests 
for the diagnosis of inflammatory disorders of the nervous system, such as 
MS (Fig. 3) [9]. In patients with a single demyelinating episode (clinically 
isolated syndrome (CIS)), detection of intrathecal immunoglobulin synthesis 
may predict progression to clinically definite MS (CDMS), and OCBs in CSF 
during the early phase of disease are associated with a worse outcome [10]. 
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Figure 3 Oligoclonal IgG are the products of oligoclonal plasma cells that secrete 
immunoglobulins, which migrate as discrete bands after electrophoretic separation. These 
bands can be detected in the CSF of most (>95%) patients with MS, persist throughout the 
course of the disease, and are a diagnostic hallmark of MS; however, their antigenic 
specificity is largely unknown [11]. 
 
The nervous system of a person with MS responds less actively to stimulation 
of the optic nerve and sensory nerves due to demyelination of such pathways. 
As an additional control in MS diagnosis, these brain responses can be 
examined using visual and sensory evoked potentials. 
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1.1.3 Therapeutic approaches 
 
Over the last two decades, therapeutic approaches to MS have emerged to 
reduce the relapse frequency and the rate of disability progression. First-line 
therapies include interferon-β formulations (Avonex, Biogen-Idec and Rebif, 
Merck-Serono)and glatiramer acetate (Copaxone, Teva). Second-line 
therapies include humanized antibodies, e.g. natalizumab (Tysabri, 
Elan/Biogen-Idec) that recognizes the α4 subunit of α4β1 integrin, a cell 
adhesion molecule expressed on lymphocytes. All of these therapies target 
the immune system and require parenteral delivery through injection or 
infusion, which can be associated with both patient compliance issues as well 
as deleterious side effects. Interferons are often associated with injection-site 
reactions and flu-like symptoms, and other less commonly reported events 
including liver dysfunction and cytopenias. Of greater concern with the 
efficacious agent natalizumab is the increasing incidence of progressive 
multifocal leukoencephalopathy (PML), 
a rare but serious infection associated with immunosuppression that has 
resulted in multiple fatalities in MS patients receiving this therapy. Another 
example of therapy is the cytostatic agent mitoxantrone, that has a cumulative 
dose-dependent cardiac toxicity with additional risk of leukemia, both of 
which limit its long-term use. Drugs under development for MS include the 
monoclonal antibodies named rituximab, ocrelizumab, and ofatumumab 
(which target CD20 to deplete B cells); alemtuzumab/ Campath-1H (which 
targets CD52 to deplete T and B cells and some monocytederived dendritic 
cells); and small molecules including the oral agents. Among others, 
cladribine (a cytotoxic adenosine deaminase-resistant purine nucleoside, 
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recently withdrawn from commercial development), dimethylfumarate BG-
12 (an activator of the nuclear factor-E2-related factor 2 (Nrf2) 
transcriptional pathway that alters glutathione levels, but is also associated 
with tumorigenesis and immunosuppression), laquinimod (unknown cellular 
target), teriflunomide (an inhibitor of dihydroorotate dehydrogenase, which 
catalyzes the rate-limiting step in the de novo synthesis of pyrimidines) and 
FTY720/fingolimod (commercial name Gilenya, Novartis; it’s the first oral 
MS therapy approved by the United States Food and Drug Administration 
(FDA), the European Union, and several other countries, which interacts with 
the sphingosine 1-phosphate (S1P)). All of these agents target lymphocytes 
as well as other immune-related cells, and currently remain subject to 
additional clinical and regulatory evaluation before possible entry into the 
therapeutic armamentarium [12]. 
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 1.2 Etiology and pathogenesis of MS 
 
The total number of people living with MS worldwide is estimated to be 2–
2.5 million. The disease is unevenly distributed throughout the world: its 
prevalence varies between < 5 cases per 100,000 people in tropical areas or 
Asia and >100–200 cases per 100,000 in temperate areas, especially those 
with large populations of Northern European origin, including the United 
States, Canada, New Zealand and parts of Australia (Fig. 4) [13]. It is a 
widely held notion that MS frequency increases progressively with 
geographic latitude in an incomplete distribution model. Nonetheless, there 
are pockets of high MS frequency such as Sardinia in the warm, southerly 
Mediterranean region [14], while among Inuit people living in Canada's cold, 
far north, MS frequency is low [15], contrary to what would be predicted 
from a simple ambient temperature/latitudinal geographic model of MS 
distribution. The irregular geographic distribution of MS and ethnic 
differences in MS frequency have attracted the interest of medical 
investigators for almost a century, reasons for its irregularity have remained 
elusive. Nonetheless, a general latitudinal gradient in MS frequency persists, 
even in recent observations [16]. The large range of incidence and prevalence 
seen in different regions in some countries does not necessarily follow 
latitudinal or other geographic gradient, and may imply the influence of both 
environmental and genetic factors [17]. 
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Figure 4  Prevalence of multiple sclerosis (x 100.000) 
 
1.2.1 Immune genetic background and immune 
pathogenesis 
 
The etiology of MS is unknown, but many findings indicate a central role of 
the immune system in the disease pathogenesis, and both genes and 
environmental factors influence the risk of developing disease. The disease 
predominantly affects northern Europeans and there is a familial recurrence 
rate of about 15%. The age-adjusted risk is higher for siblings (3%), parents 
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(2%), and children (2%) than for second-degree and third-degree relatives. 
Recurrence in monozygotic twins is around 35%. The risk for half-siblings is 
less than for full siblings. Recurrence is higher in the children of conjugal 
pairs with multiple sclerosis (20%) than in the offspring of single affected 
(2%) (Fig. 5) [2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Age adjusted recurrence risks for different relatives of probands with multiple 
sclerosis [2]. 
 
Family and genetic studies indicate a highly polygenetic mode of inheritance 
in MS. Genes responsible for complex traits are not mutations coding for 
aberrant gene products but normal polymorphisms that exert a small 
contributory effect on some as yet undefined structure or physiological 
function. Extensive searches suggested that the human leukocyte antigen 
(HLA) region is the major gene locus associated with  MS disease. The HLA-
DR1501 and HLA-DQ0601 alleles, which encode restriction elements of T 
cells, are associated with a 2–4-fold increased risk of developing MS in white 
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populations. In detail, the presence of HLA-DR1501 allele in homozygosity 
increases the risk of MS more than 6-fold [18]. For almost forty years, HLA 
has been the only genetic locus consistently linked to the disease; this 
changed in 2007 when for the first time was identified a single-nucleotide 
polymorphism (SNP) within a nonmajor histocompatibility complex (MHC) 
gene. Specifically, this gene encodes for the interleukin 7 receptor alpha 
chain (IL7R) and its non-synonymous SNP rs6897932 (T→C, T244I) is 
independent of the known HLA effect [19]. To date, Genome-Wide 
Association Studies (GWAS) have identified more than 20 additional non-
MHC risk loci containing associated SNPs and involved in disease 
susceptibility [20]. 
Altought etiology and pathogenesis of MS are still not resolved, it’s widely 
accepted that MS is a T cell-dependent autoimmune disease, with activation 
and entry into the CNS of T cells specific for myelin antigens. This view is 
based on the cellular composition of the brain, on the CSF-infiltrating cells 
and on data from the most commonly and accepted studied model of MS, that 
is EAE. Healthy individuals harbour autoreactive myelin T cells, normally 
kept in check by regulatory T cells. Failure of this regulation leads to 
proliferation, activation, and entry into the circulation of autoreactive T cells; 
they express adhesion molecules and induce reciprocal changes in endothelia, 
allowing access across the blood-brain barrier into the CNS. There, activated 
T cells re-encounter antigen and activate microglia (the CNS macrophage); 
they, in turn, express class II molecules, re-present antigen to T cells, and set 
up a proinflammatory loop. One hypothesis to explain the breakdown of 
immuneregulation in MS is the molecular mimicry, which suggests that 
peptide (the environmental factor), presented in the groove of specific class II 
molecules (one component of inherited risk), is immunologically 
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indistinguishable from self-antigen and, hence, an appropriate response to 
infection generates inappropriate inflammation against some component of 
the oligodendrocyte-myelin unit [2]. To date it’s known that immune attack 
to the nervous system by autoreactive lymphocytes that penetrate the blood-
brain barrier involves not only the cellular immunity, with T cells direct 
against myelin and oligodendrocytes, but also the humoral immunity, with 
the secretion of anti-myelin antibodies from B cells and subsequent fixation 
of complement and opsonization of the myelin sheath and the 
oligodendrocyte by macrophages (Fig. 6) [1]. 
 
 
Figure 6. Immunopathogenesis of multiple sclerosis. Activated antigen-specific T cells and 
B cells cross the blood–brain barrier and target self antigens expressed by oligodendrocytes 
and neurons [21]. 
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Although all the major immune cell types have been implicated in the 
pathogenesis of MS, CD4+ and CD8+ T cells being the most commonly and 
historically studied. In general, CD4+ T helper cells (Th) recognize peptides 
that are presented by MHC class II molecules on specialized antigen-
presenting cells (APC) and are usually derived from antigens ingested by the 
APC. Once activated, naive Th cells differentiate into functional subsets: the 
so-called pro-inflammatory Th1 cells, which predominantly produce 
interferon (IFN)-g and tumour necrosis factor (TNF)-a, protect against 
intracellular pathogens; and Th2 cells, which produce interleukin (IL)-4, IL-5 
and IL- 13, and help to combat extra cellular infections. By contrast, CD8+ T 
cells mostly recognize peptides from the endogenously synthesized antigens 
presented by MHC class I molecules which, in general, are expressed by all 
nucleated cells. They mediate effector functions through production of 
cytokines, such as IFN-g and TNF-a, and/or by direct cytotoxicity [3]. 
CD4+ T cells have long been presumed to play an almost exclusive role 
throughout the disease. This hypothesis was supported by many parallels 
with EAE, that can be adoptively transferred to mice by the injection of 
encephalitogenic myelin-specific Th cells, and also by the fact that certain 
HLA class II molecules represent the strongest genetic risk factor for MS, 
presumably via their role as antigen-presenting molecules to pathogenic 
CD4+ T cells [3]. The necessity to re-evaluate the role of different cell types 
in MS was suggested when a phase II clinical trial testing the effect of 
Ustekinumab, an antibody directed against the common subunit of IL-12 and 
IL-23, relevant for Th1 and Th17 cell differentiation respectively, reported no 
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benefit in RRMS [22]. In confirmation, another antibody directed against 
CD4, which successfully depleted CD4+ T cells, was also found to have no 
effect on disease activity or course in patients with MS [23]. In clear contrast, 
analogous antibodies prevented the development of EAE in animals [24]. 
These trials even demonstrate why, although animal models represent useful 
and essential tools in modern research, one needs to be aware of their 
distance from the human disease. Recently, the interest toward CD8+ T 
lymphocytes has been strengthened by several reports showing their 
contribution to CNS tissue damage and the correlation with progression and 
severity of disease [25; 26]. In demyelinating plaques, CD8+ 
usually outnumber CD4+T cells and undergo local clonal expansions more 
frequently than CD4+T cells. Moreover, specific enrichment and oligoclonal 
expansions of memory CD8+ T cells were found in CSF of MS patients [27; 
28]. Based on the fact that the model of MS as a disorder mediated only by T 
cells is overly simplistic, further studies have proposed an important role 
even for B cells in the propagation of the disease. For this reason, over the 
past two decades B cells have increasingly moved into the spotlight in MS 
research. Growing understanding and acceptance of pathological involvement 
of B cells and antibodies in MS derived from data in animal models of MS, 
human histopathological studies, and analyses of B cells in the peripheral 
blood and CSF [29]. In particular has been noticed that most active MS 
lesions from autopsy are composed of a mixed population of T and B cells 
and characterized by the deposition of immunoglobulins, Fcγ receptors and 
terminally activated complement [30; 31]. Furthermore, B lymphocyte 
infiltration into the CNS and levels of intrathecal IgG synthesis correlate with 
disease severity and parenchymal inflammation [32], and anti-B cell 
therapies are the only cell-specific treatments efficacious in RRMS patients 
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[33]. Lastly, environmental factors associated with MS susceptibility 
(vitamin D and the EBV) influence B cell proliferation and function. 
Specifically, vitamin D plays an important role in B cell homeostasis by 
decreasing cell proliferation, inducing apoptosis, inhibiting plasma cell 
differentiation, and regulating the expression of genes associated with MS 
susceptibility in B cells (including HLADRB1, CD40, CXCR4, and 
CXCR5); EBV establishes a latent infection in B cells, promoting their 
proliferation and activation [34]. 
Although the precise role of B cells in disease is presently unknown, it could 
involve antigen presentation to pathogenic T cells, the production of 
proinflammatory cytokines, or the synthesis of antibodies to unknown viruses 
or autoantigens that promote oligodendrocyte loss or tissue destruction. 
A growing number of recent publications have emphasized the potential 
importance of B cells in the pathology of MS. The renaissance of this 
relatively neglected area reflects an increasing appreciation of the failings of 
standard T cell dominated animal models of CNS demyelination fully to 
represent the human disease and its response to treatment [35]. In fact EAE, 
induced in animals by intradermal injection with whole or parts of various 
proteins that make up myelin or directly with myelin-specific Th cells, only 
resembles some forms and stages of MS; hence, a number of significant 
assumptions made when proposing EAE as MS may only be partially true 
[36]. In parallel, there has been a progress in our knowledge of the basic 
immunology of the B cell lineage in terms of both antibody-dependent and 
antibody-independent roles. Currently it’s well-known that B cells may be 
involved at many levels in the pathogenesis of MS, starting from the earliest 
stage of antigen capture, continuing through the processes of tissue damage 
and even extending through to remyelination and repair [35]. 
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1.3 Environmental factors: non infectious factors 
 
Epidemiological and clinical studies have shown that environmental factors 
such as infections, smoking and vitamin D are associated with the risk of 
developing multiple sclerosis (MS). Furthermore, the high discordance rate 
among monozygotic twins as well as the multitude of migration and 
epidemiological studies that show latitude-dependent north to south gradient 
of increasing disease incidence (in the northern hemisphere and the opposite 
in the southern) and remarkable differences in risk among people of common 
ancestry who migrate to areas of low or high MS prevalence [37], indicate 
that MS is a complex multifactorial disease that results from the intricate, yet 
not well-understood, interaction of both genetic and environmental factors. 
The quest for identification of the potential environmental triggers of MS has 
been ongoing for decades. Both infectious and noninfectious agents have 
been implicated as potential culprits.  Yet, the plethora of controversy in the 
field makes it difficult to discern one single environmental factor as a sole 
trigger of MS. Rather it is more likely that MS susceptibility is dependent on 
the elaborate interaction of a variety of low penetrance genetic factors and 
environmental agents conveying by themselves low risk, but when combined 
together resulting in disease initiation. 
Recent epidemiological studies have identified new risk factors, not only 
associated with the risk of developing MS, but also, and perhaps more 
immediately important, with the MS disease course. While previous factors 
associated with MS disease course, such as gender or the age at disease onset, 
are not modifiable, the newly identified factors such as smoking and vitamin 
D levels are modifiable through individual and public health measures. 
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Future studies on risk factors in MS will need to build upon the classical 
epidemiological studies and integrate the new factors into the “big picture”. 
Such studies will need to unravel how the whole set of classic and newly 
identified factors interact with each other, how they are modulated by 
immunomodulatory drugs, genetic factors, gender and hormones, and at 
which stages of disease they have their greatest impact [38]. 
 
1.3.1 Vitamin D 
 
Among the non-infectious environmental triggers, there is a recent upsurge in 
studies investigating the effects of vitamin D levels on MS pathogenesis. 
Vitamin D is a potent immunomodulator affecting proinflammatory pathways 
as well as the number and activity of regulatory T cells [39]. Epidemiological 
studies have shown an increase in MS frequency with increasing distance 
from the equator, which inversely correlates with duration and intensity of 
sunlight. Interestingly, populations situated at high latitudes but having high 
consumption of vitamin D rich food were observed to have reduced MS 
prevalence while the risk of MS incidence decreased with movement from 
high to low altitudes [37]. Timing of birth has also been implicated as a 
predictor of MS susceptibility. A study including a large data set of more 
than 40000 MS patients from Sweden, Denmark, Canada and Great Britain 
revealed that significantly fewer individuals with MS were born in 
November, while the incidence of MS was significantly higher for people 
born in May, indicating an association between prenatal sunlight and risk of 
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MS. Interestingly, the effect of month of birth was more evident for familial 
cases, suggesting a potential gene/ environment interaction [40]. There is also 
mounting evidence that vitamin D influences the disease course of MS. 
Cross-sectional studies showed that low levels of vitamin D and lower bone 
mineral density, are common in MS, and lower vitamin D levels are 
associated with higher levels of disability [41]. Although other immune 
modulatory mechanisms potentially exist for ultraviolet radiation [42], the 
association of sunlight with MS is most likely due to the ultraviolet B 
radiation of sunlight (290–320 nm) converting cutaneous 7-
dehydrocholesterol to previtamin D3, which then spontaneously forms 
vitamin D3. The latter then undergoes 2 hydroxylations, most notably in the 
liver and kidney by D-25-hydroxylase (CYP2R1) and 25-hydroxyvitamin D-
1α-hydroxylase (CYP27B1), to produce the biologically active form of 
vitamin D, 1,25-dihydroxyvitamin D3 (Fig. 7). Notably, variants of the 
CYP27B1 gene have been found to be associated with increased risk of MS 
[43]. Another study found association of MS with CYP27B1 and a second 
region containing another vitamin D associated gene, CYP24A1 [20], a 
vitamin D response element lies close to the promoter region of HLA-DRB1, 
the main risk allele for MS [44]. 
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Figure 7 Fate of vitamin D from skin to blood circulation [48] 
 
The utility of vitamin D in MS is almost certainly due to its multiple 
immune-regulating properties that impact on the majority of the 
immunopathogenic steps outlined in figure 8. Vitamin D suppresses the 
maturation and activity of APCs, including dendritic cells, or increases their 
“tolerogenic” phenotype, thereby reducing the probability of presenting self-
antigens to generate autoreactive cells, or decreasing the likelihood of 
expanding autoreactive cells through molecular mimicry. 
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Figure 8 Steps in the immunopathogenesis of MS and modulation by environmental factors 
[47]. 
 
The differentiation of CD4+T helper cells is also affected by vitamin D, with 
a reduced production of pro-inflammatory Th1 and Th17 cells [45]; 
concurrently, Th2 cells are increased, thereby helping to reduce the pro-
inflammatory state that typifies MS. Other major immunologic consequences 
of vitamin D treatment are the increased activity of regulatory T cells and the 
reduction of pro-inflammatory molecules produced by stimulated monocytes. 
These immunologic changes caused by vitamin D can be detected in culture, 
in samples obtained from MS patients and in EAE. In EAE, treatment with 
vitamin D either prevents the development of symptoms when given early in 
the disease course, or reduces the severity of EAE when treatment is initiated 
at onset of clinical signs or at peak disease. Vitamin D is known to penetrate 
into the CNS, and it may potentially have several activities within the CNS 
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including the reduction of antigen presentation to reduce neuroinflammation. 
More intriguing is the possibility that vitamin D may be neuro-protective. 
The enzymes necessary to synthesize the bioactive 1,25-dihydroxyvitamn D3 
are present in the brain [46]. Overall, there is substantial evidence that 
vitamin D corrects many of the immune abnormalities seen in MS. It is not 
clear which of its multiple mechanisms are most critical to its therapeutic 
efficacy. Whether some of the benefits of vitamin D may relate to its actions 
within the CNS remains to be determined [47]. 
 
1.3.2 Smoking 
 
A history of cigarette smoking has been almost unanimously associated with 
increased susceptibility to MS.  It remains to be determined whether smoking 
is indeed an independent risk factor for MS development. The biological 
mechanisms that would link smoking to the pathogenesis MS are elusive. 
Nicotine, however, is not be the sole culprit since studies have shown that use 
of tobacco snuff does not increase the risk of MS [49].  It is not known how 
smoking increases the risk of MS and although cigarette smoke contains 
many mutagens which potentially may affect long lasting immunity, a recent 
review indicates that smoking generally leads to an immunosuppressant state 
[50]. Nonetheless, aspects of immune functions are promoted by cigarette 
smoking and genetic studies indicate an interaction between smoking and 
genes that regulate immune function [51]. However, it is highly improbable 
that this environmental factor alone account for the worldwide variation in 
MS prevalence [47]. 
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Observational studies suggest that cigarette smoking may exert an influence 
on the course of established MS. Outcomes that have been linked to smoking 
effects include measures of disease activity (clinical relapses and 
development of new lesions visible on MRI), more rapid conversion from a 
first ever demyelinating clinical event (also known as a clinically isolated 
syndrome (CIS), typically optic neuritis or partial myelitis) to confirmed MS, 
the rate of conversion from relapsing–remitting to secondary progressive MS, 
and the rate of neurological deterioration once progressive MS has been 
established. Evaluation of the magnitude of the effect of smoking on the 
course of established MS may shed light on underlying disease mechanisms 
and is important because more than half of MS patients smoke at some time 
[52]. The epidemiological evidence reported to date suggests that smoking is 
probably associated with a greater risk of conversion from relapsing–
remitting to secondary progressive MS. Early and heavier cigarette 
consumption may increase the risk of primary progressive MS compared with 
a relapsing–remitting onset. Smoking may increase the rate of conversion 
from CIS to confirmed MS and increase the rate of accumulation of disability 
in established progressive forms of MS. The effects of smoking on the 
response to disease-modifying therapy are not known [53]. 
 
1.3.3 Diet 
 
It is commonly accepted that nutrition is one of the possible environmental 
factors involved in the pathogenesis of multiple sclerosis (MS), but its role as 
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complementary MS treatment is unclear and largely disregarded. At present, 
MS therapy is not associated to a particular diet, probably due to lack of 
information on the effects of nutrition on the disease. To overcome the 
distrust of the usefulness of dietary control in MS and to encourage 
nutritional interventions in the course of the disease, it is necessary to assess 
the nature and the role of bioactive dietary molecules and their targets, and 
establish how a dietary control can influence cell metabolism and improve 
the wellness of MS patients [54]. Studies on the relationship between diet and 
MS are very few, and diets available to the MS patient are often lacking a 
scientific basis. There is, however, an apparently great need to apply non-
conventional therapies, and the majority of MS patients often use 
complementary or alternative treatments without informing the physician 
[55]. The most intriguing aspects of MS are perhaps its uneven geographical 
distribution and the influence of migration in young age on disease course 
[56]. To understand how diet can exacerbate or ameliorate MS symptoms, it 
is necessary to identify the dietary molecules, their targets and the molecular 
mechanisms involved in the control of the disease [54]. Cells possess specific 
sensors to adapt themselves to changes in their environment, and changes in 
content and type of food molecules are the most common over time. Dietary 
molecules exert their direct influence on metabolism by modulating the 
expression and the activity of enzymes, hormones, transcription factors, and 
nuclear receptors [57]. The influence of dietary molecules and some common 
drugs on metabolism and inflammation is sketched in figure 9. 
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Figure 9 Schematic representation of the influence of some natural dietary compounds and 
some common drugs on cell transcriptional activity in metabolism and inflammation [54]. 
 
In MS, the transcription factors involved in inflammation and autoimmunity, 
the activator protein (AP-1) and the nuclear transcription factor kB (NF-kB), 
are activated and induce the expression of several pro-inflammatory genes 
and the production of pro-inflammatory molecules. The peroxisome 
proliferator-activated receptors (PPAR/RXR) complex exerts a tight control 
over the expression of inflammatory genes by inhibiting NF-kB and AP-1, 
thus integrating metabolic and inflammatory signaling by inhibiting 
inflammatory gene expression. Thus, through their binding to PPARs or 
directly by their binding to NF-kB and AP-1, dietary molecules can inhibit 
the inflammatory process [58].  
Among the dietary factors that have been considered most frequently for their 
deleterious influence on MS are saturated fatty acids of animal origin. In 
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1950, Swank suggested that the consumption of saturated animal fat is 
directly related to the frequency of MS, and in 2003 Swank and Goodwin 
reported that restriction of saturated fat induces remission of the disease. 
These effects were ascribed to the formation of large fat aggregates and 
obstruction of small capillaries. However, the influence of fat on cells is 
certainly more complex, since it is directed towards gene expression and cell 
growth and differentiation  and is controlled at transcriptional level [57; 59]. 
Moreover, animal fats lead to the synthesis of cholesterol and decrease 
membrane fluidity, activate the CD14/TLR4 receptor complex, increase 
blood levels of C-reactive protein, and lead to the formation of TNF-alpha 
and to dysbiotic gut microbiota. 
Environmental (microbial or dietary) factors can be associated with 
autoimmunity by molecular mimicry [60] and epidemiological studies have 
shown that some proteins from cow’s milk could be responsible for the link 
between milk consumption and MS [61] Abnormal T cell immunity to 
several cow milk proteins was observed in MS patients and in children with 
autoimmune disease and CNS injury. However, the milk proteins that appear 
to be more detrimental in MS are the proteins of the milk fat globule 
membrane (MFGM proteins) and in particular butyrophilin (BTN). BTN is 
very similar to myelin oligodendrocyte glycoprotein (MOG), the MS 
candidate autoantigen, and induces experimental inflammatory responses in 
the CNS. MOG/BTN cross-reactive antibodies have been found in MS [62]. 
Specific dietary molecules might be able to counteract inflammation, 
autoimmunity, oxidative stress, and angiogenesis associated with MS, and for 
this reason they are considered as ‘‘healthy’’ molecules that can improve the 
wellness of MS patients. Polyphenols are bioactive molecules found in 
vegetables, fruits, spices, herbs, soy, tea, wine and other fruit-based 
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beverages [63]. These dietary molecules are well known for their antioxidant 
activity, but recent findings indicate that they have additional neuroprotective 
properties, independent of their roles as antioxidants and radical scavengers. 
Polyphenols include well-known flavonoids (quercetin, catechins, genistein) 
and non-flavonoids (resveratrol, hydroxytyrosol and curcumin) molecules. 
Most polyphenols contain the catechol group, which has been recently 
associated with anti-inflammatory activity in stimulated microglia and 
neutrophils [64].  In general, polyphenols have antioxidant, antibacterial, 
antifungal, antiviral, anti-aging, anti-angiogenic, anti-carcinogenic, anti-
proliferative and anti-inflammatory effects, and have been found to prevent 
neurodegenerative, cardiovascular, metabolic, autoimmune, and neoplastic 
diseases. They pass the blood brain barrier and ameliorate experimental 
allergic encephalomyelitis (EAE) [65; 66; 67; 68; 69]. 
Unsaturated vegetable oils are the alternative to saturated animal fat. They 
contain the essential fatty acids linoleic acid (n-6) e linolenic acid (n-3). The 
n-6 and n-3 fatty acids have opposing effects and their intake in the diet 
should be equivalent in healthy individuals. However, in Western diets, the n-
6/n-3 ratio is largely increased and this causes a greater incidence of 
cardiovascular and inflammatory diseases. Few clinical trials indicate that n-3 
PUFA may represent a good complementary treatment in the course of MS 
[70; 71]. Fish oil may be useful also in healthy conditions to improve motor 
performances. Seed oils, from sunflower, corn, soybean, and sesame, contain 
more n-6 than n-3 fatty acids and their consumption should be limited in MS. 
Coconut oil has a high content of saturated fatty acids and is not indicated for 
MS patients. Olive oil is a good alternative to the oils reported above. 
Hydrogenated fatty acids are found in margarine and in other treated fat, or 
are formed in frying. Differently from the natural ones, they are trans fatty 
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acids (TFAs) and interfere with PUFA metabolism. The TFAs show pro-
inflammatory effects and increase the levels of IL-6, TNF- -reactive 
protein [72].  
As discussed above, vitamin D plays an important role in the pathogenesis of 
MS linked to geographic latitude and exposure to the sun. Also, nicotinic acid 
and vitamin B12, vitamin E and vitamin C should be taken into consideration 
[73; 74]. In particular, niconitic acid activates the PPARs (indirectly) and the 
sirtuins (directly), stimulates the synthesis of prostaglandins 15d-PGJ2 and 
PGE2, raises HDL levels, corrects dyslipidemia, and in the form of 
nicotinamide protects the CNS from demyelination. Oligoelements and other 
useful compounds with antioxidant activity that can be associated to the MS 
diet are: selenium, alpha-lipoic acid (ALA), N-acetylcysteine94 (NAC) and 
glutathione. ALA has immunomodulating effects, inhibits T cell migration, 
stimulates cAMP production, inhibits IFN-gamma synthesis, and is effective 
in the treatment of EAE. NAC, a precursor of reduced glutathione, is 
beneficial for antioxidant protection and energy metabolism [75; 76].  
Recent research data from in vivo and in vitro experiments appear to 
substantiate at molecular level a clear anti-inflammatory role of hypocaloric, 
low-fat diets and bioactive dietary supplements, and suggest that they might 
slow down the occurrence of relapses in relapsing-remitting MS. These 
evidences open new perspectives for further clinical trials based on the 
complementary treatment of chronic inflammatory diseases such as MS. 
However, the most important challenges in the future are represented by 
clinical studies. Clinical trials should be done by teams of neurologists, 
nutritionists, gastroenterologists and physiotherapists or exercise trainers to 
assess the impact of a nutritional intervention and exercise on the frequency 
of relapses and the wellness of patients [54]. 
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1.4 Infectious environmental factors 
 
The hypothesis of an infectious etiology of MS was advanced many years 
ago, at the time that the disease was described by JM Charcot. His student, 
Pierre Marie, in 1884 asserted an infectious etiology for MS, with the 
possibility of the development of a vaccine against the disease. Several 
studies implicate infectious and non-infectious environmental factors present 
during childhood and young adulthood as strong determinants of MS risk, 
although their nature remains unidentified [77]. Microbial infections can act 
as triggers inducing or promoting autoimmunity, resulting in clinical disease 
manifestations in genetically predisposed individuals. Alternatively, 
infections might accelerate sub-clinical autoimmune processes [78]. Many 
hypotheses have been proposed to help explain to what extent an infectious 
agent might affect MS epidemiology. The ‘polio’ hypothesis, postulates viral 
infections acquired in late childhood or adulthood increase MS risk, but cause 
little harm and confer protective immunity when acquired in infancy [79]. 
Another theory, proposed by Kurtzke, is the prevalence hypothesis, based on 
investigations conducted during the Faroe Islands epidemic. It postulates MS 
is caused by a pathogen, common in regions of high disease prevalence, a 
widespread agent causing asymptomatic and persistent infection in most 
individuals which may generate neurological symptoms years later [80]. As 
experience with infectious pathogens accumulated, particularly viruses, the 
possibility of a viral etiology of MS became more acceptable (Table 1). With 
the demonstration of a viral etiology of progressive multifocal 
leukoencephalopathy and subacute sclerosing panencephalitis, interest in 
viruses increased considerably. The biologic evidence for an infectious 
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etiology for MS includes the association of MS with infectious 
mononucleosis, the presence of pleocytosis, and the intrathecal synthesis of 
antibodies and oligoclonal bands detectable in the cerebrospinal fluid (CSF), 
high immune reactivity to particular viruses, and the example of other human 
and animal viral demyelinating diseases [81]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Viral detection from MS brain or CSF [81] 
 
The hypothesis of “bystander activation” postulates that autoreactive T cells 
are activated by nonspecific inflammatory molecules occurring during 
infections, such as cytokines, superantigens and toll-like receptor ligands [3]. 
Yet another hypothesis is that viruses activate immune cells through the 
process of “molecular mimicry” [82]. The hypothesis postulates that upon 
exposure to a pathogen, the pathogen/MHC conformation on an APC bears 
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molecular similarity to that of a endogenous peptide, such as a fragment from 
myelin basic protein (MBP), presented within an MHC. If co-stimulatory 
molecules are properly engaged, the result could be the expansion and 
differentiation of not only the pathogen-reactive T cells, a properly directed 
immune response, but also the expansion of MBP-reactive T cells, an 
improper outcome. If both pools differentiate into Th1 or Th17 pro-
inflammatory subsets these can become reactivated within the CNS to 
promote pathology. In support of this idea, T cell lines isolated from MS 
patients demonstrate cross-reactivity between MBP and corona virus or 
Epstein-Barr virus (EBV) antigens [83]. Overall, given that, there are several 
pathogens with molecular similarity to a number of myelin peptides and other 
molecules within the CNS, the probability is high that several viruses can 
lead to the improper expansion of CNS-reactive T cells that can promote 
pathology within the CNS. For this reason it will be difficult to pinpoint a 
single infectious pathogen uniquely associated with MS [47]. 
 
 
1.4.1 Viral infections: EBV 
 
The Epstein–Barr virus (EBV), also called human herpesvirus 4 (HHV-4), is 
a virus of the herpes family, and is one of the most common viruses in 
humans. EBV has the unique ability to infect, activate and latently persist in 
B lymphocytes for the lifetime of the infected individual [84]. It is 
transmitted by oral contact (‘kissing disease’) and readily infects the 
recipient. On the basis of careful epidemiological studies, Niederman et al.  
showed that of all acute EBV infections, there were two who were 
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symptomatic infectious mononucleosis to each asymptomatic infection [85]. 
In children, acute EBV is generally asymptomatic, whereas in young adults, 
the clinical illness known as infectious mononucleosis (IM) usually occurs. 
In the higher latitudes, infection is acquired later in life and is, therefore, 
much more common than near the equator [86]. 
During primary infection, EBV transmitted via saliva infects naive B cells in 
the tonsil through binding of the viral surface glycoprotein gp350 to 
complement receptor 2 (CR2; also known as CD21), which is expressed by 
mature B cells and follicular dendritic cells [87]. EBV drives the infected B 
cell out of the resting state to become an activated B blast and then exploits 
the normal pathways of B cell differentiation so that the B blast can become a 
latently infected resting memory B cell (Fig. 10) [88].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 A model for Epstein–Barr virus (EBV) infection and persistence. This model is 
derived from work published by Thorley-Lawson and colleagues [88]. 
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To achieve this, the virus deploys a series of different latency transcription 
programs. On initial infection of naive B cells, EBV uses the latency III or 
“growth” program in which all viral latent proteins are expressed—namely, 
the Epstein-Barr nuclear antigens (EBNA) 1, 2, 3A, 3B, 3C, and LP and the 
latent membrane proteins (LMP) 1, 2A, and 2B. This activates the B cell to 
become a B blast, which then enters a germinal center in the tonsil where it 
down-regulates the expression of the EBNA proteins 2, 3A, 3B, 3C, and LP. 
The continuing expression of EBNA1, LMP1, and LMP2 (latency II or 
“default” program) allows the infected B cell to progress through a germinal 
center reaction to become a memory B cell, which exits from the germinal 
center and circulates in the blood. The EBV-infected memory B cell 
expresses no viral proteins except during cell division, when it expresses only 
EBNA1 (latency I), which engages the host cell DNA polymerase and 
ensures transmission of the viral genome to the daughter cells. The lack of 
viral protein expression allows the virus to persist in memory B cells despite 
a healthy immune response [88]. Latently infected memory B cells returning 
to the tonsil and they can terminally differentiate into plasma cells, which 
initiates the lytic (replicative) transcription program with the production of 
infectious virus.              The resulting free virions infect tonsil epithelial 
cells, where the virus replicates at a high rate and is continuously shed into 
saliva for transmission to new hosts [89]. Newly formed virus can also infect 
additional naive B cells in the same host. Latently infected memory B cells 
display the molecular hallmarks of classical antigen-selected memory B cells 
namely, somatic hypermutation and class-switch recombination of their 
immunoglobulin (Ig) genes [90]. In normal B cell differentiation, naïve B 
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cells are activated by antigen through the B cell receptor (BCR) and by T cell 
help through the CD40 receptor so that they proliferate and progress through 
a germinal center reaction. Remarkably, LMP2A and LMP1, which are 
expressed by EBV during latency II and latency III, mimic the antigen-
activated BCR and the activated CD40 receptor, respectively. In vitro 
LMP2A can mimic and replace constitutive BCR signalling and thereby 
support an activated, proliferative state in B cells, which it renders resistant to 
apoptosis [91]. EBV infection is normally kept under tight control by EBV-
specific immune responses, especially by cytotoxic CD8+ T cells, which 
eliminate proliferating and lytically infected B cells [92]. Even if, during the 
incubation period, the cycle of infection, B cell activation, germinal center 
reaction, lytic replication, and reinfection initially goes unchecked by 
cytotoxic CD8+ T cells because of the delay in mounting an adaptive 
immune response. As a result, the number of latently infected memory B 
cells during infectious mononucleosis can rise to half and perhaps even 
higher of the peripheral memory B cell compartment. Eventually, the 
infection evokes a massive expansion of activated EBV specific CD8+ T 
cells, which rapidly control the infection by killing a high proportion of the 
EBV-infected B cells. With the rapid decline in the EBV viral load, the 
number of EBV-specific CD8+ T cells also rapidly declines toward the levels 
found in persistently infected healthy virus carriers. It has been suggested that 
the difference between asymptomatic primary EBV infection and infectious 
mononucleosis is the higher number of EBV-infected B cells in the latter, 
with the symptoms being due to the massive destruction of virus-infected B 
cells by cytotoxic CD8+ T cells [93]. Why a higher proportion of B cells 
should be infected when primary infection is delayed beyond childhood to 
adolescence or later is unclear. Possible explanations include a higher dose of 
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viral inoculum acquired by intimate oral contact and a reduced capacity to 
mount a rapid effective CD8+ T cell response in adolescents/adults compared 
with young children. The importance of CD8+ T cells in controlling primary 
EBV infection is demonstrated by the development of potentially fatal B cell 
lymphoproliferative disease in immunosuppressed transplant recipients with 
low numbers of EBV-specific T cells and high viral loads [94]. 
 
1.4.2 Role of Epstein-Barr virus in the risk of MS 
 
There is now substantial evidence that infection with the EBV plays a major 
role in the development of MS. It is important to distinguish the role of EBV 
from that of other infectious agents in MS. It is well established that clinical 
exacerbations of MS are three times more likely to occur at the time of acute 
systemic infection with a wide variety of viruses and bacteria than at other 
times [95]. Several reviews as well as ecological studies suggest that the 
similar latitudinal distributions of infectious mononucleosis (IM) and MS are 
evidence of an association [96; 97; 98] . Warner et al. noted that classical IM 
and MS were both uncommon in African, Oriental and Polynesian 
populations, with the high incidence of IM “a characteristic of affluent 
Caucasians’ ” that is, socioeconomic status was considered the important risk 
factor [99]. A later age of EBV infection has been suggested as a key MS risk 
factor that could explain persisting latitudinal gradients in incidence of CNS 
demyelination or loss of a previously observed latitude gradient. Certainly, 
the prevalence of seropositivity in childhood appears to be higher in less 
developed countries compared with more developed regions but no study has 
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yet shown whether the age specific prevalence of EBV seropositivity varies 
by latitude after the level of development is considered that is, within a single 
country with relative homogeneity of socioeconomic status [100; 101; 102]. 
An associated risk for MS following EBV infection, but not 
cytomegalovirus- or HSV1-infection, was also found in cases of pediatric MS 
[108]. Individuals who acquire EBV during adolescence or later, as 
manifested by infectious mononucleosis, are at an additional 2–3-fold higher 
risk to develop MS than children infected early in life [104]. Heightened 
humoral immune responses to EBV are found in individuals with MS. 
Notable differences in antibody titers to EBV antigens, particularly EBNA-1 
and the nuclear EBNA complex, are detected in MS patients up to five years 
before the diagnosis of disease. Compared with matched controls, increased 
EBV Antibodies (Ab) titers indicate an increased risk for developing MS 
disease and are suggested to be an early event in the disease process [105; 
106]. The association between enhanced EBV immunity and the role of EBV 
as a causative agent is complicated by elevated Ab titers in MS serum and 
cerebrospinal fluid (CSF) to many common viruses and infections prevalent 
within the human population, which may be more indicative of an overall 
immune dysregulation of B cell memory responses [107]. Cellular immunity 
is also somewhat altered in MS patients relative to healthy controls. 
Generally, there are increased numbers of circulating EBV-specific CD8+ 
cells but not EBV-specific CD4+ T cells, the exception being EBNA-1 [108]. 
EBNA-1-specific memory CD4+ T cells are elevated in MS blood, show 
increased proliferative capacity and possess higher avidity and broadened 
peptide specificity compared with demographically and HLA-DR matched 
controls. Although the epidemiologic and immunologic data provide a 
compelling connection between exposure to EBV and risk of MS, alternative 
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explanations that do not necessitate a direct causal link cannot be excluded, 
the most likely being a shared susceptibility for MS and EBV infection [109]. 
Important clues are emerging from studies that are beginning to delineate 
specificities of the humoral immune response to Epstein–Barr nuclear 
antigen-1 (EBNA-1) [110,111]. The combination of DRB1*1501 haplotype 
with high-titer responses to the whole EBNA-1 protein or to a particular 
sequence domain markedly increased the risk of MS [112]. Mechelli and co-
workers analyzed the fine specificity of the humoral immune response to 
EBNA-1 in MS-discordant monozygotic (MZ) twins, a setting that 
considerably decreases the influence of heritable and non-heritable 
confounders [113; 114; 115]. They observed that the humoral immune 
response to EBNA-1 in MS frequently comprises an epitope that overlaps 
with a portion of EBNA-1 which is targeted during IM [116]. This specificity 
wanes over time in asymptomatic virus carriers. This epitope narrows down 
other EBNA-1 specificity domains 3,4 that had been described as associated 
with an increased risk of MS. These findings may provide an interpretative 
key for two consistent epidemiological observations: the association of MS 
with EBV serology and with a history of IM. IM is an immunopathologic 
disease ‘per se’ since its symptoms correlate, also temporally, with the 
immunologic alterations and not necessarily with virologic changes. It has a 
profound impact on the immune system not only during the acute phase. The 
enduring presence of a B-cell response that normally wanes after IM may 
increase and prolong the risk of immunopathology [113]. In addition to anti-
EBV antibodies being increased in the serum in MS, they are also elevated in 
the CSF, which could indicate specific synthesis of antibody against EBV or 
simply reflect polyspecific antibody synthesis. The corrected Antibody Index 
makes this distinction and reveals specific anti-EBV antibody synthesis in the 
41 
 
CNS, which is also demonstrated by the reactivity of some of the 
characteristic CSF oligoclonal IgG bands to EBV proteins. Indeed, the anti-
EBV response is the dominant antibody response in the CSF in MS, as 
revealed by Cepok and others, who screened CSF IgG for reactivity against 
37,000 proteins and found the two most frequent reactivities to be against the 
EBV proteins, EBNA1 and BRRF2. Further indirect evidence that EBV is 
present in the CNS in MS is provided by the finding that EBV-specific CD8+ 
T cells are enriched in the CSF, compared with the blood, in early MS but not 
in patients with other inflammatory neurological diseases [117; 118; 119; 
120].  In a recent work Angelini et al. show that MS patients with inactive 
disease exhibit a lower CD8+ T-cell response to EBV when compared to 
healthy donors and active MS patients while the latter have a higher 
frequency of CD8+ T cells specific for EBV lytic antigens. Therapy with 
interferon-b and natalizumab, two treatments for relapsing remitting MS, was 
associated with marked changes in the EBV specific CD8+ T cell response. 
They also demonstrate that one of the EBV lytic antigens, recognized by 
CD8+ T cells expanding in the blood during active MS is expressed in the 
inflamed MS brain [121]. The recruitment of CD8+ T cells was selective for 
EBV specific T cells because T cells reactive to cytomegalovirus, another 
herpesvirus, were not enriched in the CSF. Given that antigen-specific CD8+ 
T cells infiltrate the brain only when their cognate antigen is present, these 
findings suggest that EBV is present in the CNS in MS [122]. An alternative 
but less likely explanation is that EBV-specific CD8+ T cells in the CSF are 
recognizing not EBV but a CNS autoantigen with which they cross-react. 
Recently, Serafini and others reported that a substantial proportion of the B 
cells and plasma cells in 21 of 22 brains of MS patients were infected with 
EBV [123]. They identified EBV-infected cells using in situ hybridization for 
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EBV-encoded small RNA (EBER-ISH), the gold standard for detection of 
EBV-infected B cells in histological material and by immunohistochemistry 
with antibodies specific for EBV proteins [124]. EBV-infected B cells were 
not detected in the brains of patients with other inflammatory CNS diseases. 
The major sites of EBV persistence in the MS brain were meningeal 
structures resembling B cell lymphoid follicles with germinal centers, which 
the authors had previously demonstrated to be present in patients with 
secondary progressive MS (Fig. 11) [125]. B cells expressing EBV latent 
proteins were regularly found in the brains of patients with MS, whereas B 
cells expressing the EBV early lytic cycle protein, BFRF1, were restricted to 
acute lesions and meningeal B cell follicles. Their finding that EBV-infected 
B cells in meningeal follicles express LMP1 and LMP2A but not EBNA2 
indicates that here EBV deploys the latency II (“default”) transcription 
program  which allows infected B cells to progress through a germinal center 
reaction to become latently infected memory B cells [88; 123; 126]. It also 
accords with the observation that, in the tonsils of healthy EBV carriers, 
EBV-infected B cells expressing this viral transcription program not only are 
functionally indistinguishable from classical germinal center B cells but also 
are physically located in germinal centers [127]. In contrast, Willis and others 
found EBV in only 2 of 24 brains of MS patients. They did not detect EBV-
infected B cells by EBER-ISH or immunohistochemistry using antibodies 
against LMP1 or EBNA2 in any of the specimens but did detect low levels of 
EBV DNA in two samples by realtime polymerase chain reaction. They 
concluded that EBV infection is rare in MS brain tissue and unlikely to 
contribute directly to the pathogenesis [128]. Possible explanations for the 
discrepancy between these findings and those of Serafini and others, are 
differences in experimental design and interpretation, tissue selection and 
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processing, the degree of CNS B cell infiltration, and the sensitivities and 
specificities of the techniques used. It has been suggested that the inability of 
Willis and others to detect any EBV-infected B cells by EBER-ISH in their 
MS brain specimens might have been due to degradation of EBER RNA by 
long tissue fixation times in formalin [129].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Epstein-Barr virus (EBV)–infected B cells in the brain in secondary progressive 
multiple sclerosis (MS). This distribution of EBV-infected B cells in the MS brain is based 
on the study of Serafini and others [123]. 
 
 
Lünemann and others found the EBV DNA load in peripheral blood 
mononuclear cells (PBMCs) to be moderately increased in patients with 
clinically isolated syndromes (first episodes of the type seen in MS) 
compared with healthy subjects [108]. Using the same assay in an earlier 
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study, the same group concluded that the EBV viral load is not increased in 
the PBMCs of patients with relapsing–remitting MS; however, the viral load 
was substantially higher in the MS patients than in the healthy controls, 
although the difference was not statistically significant, possibly because of 
the small numbers of subjects [130]. There is strong evidence that EBV 
infection precedes MS onset and there is a dose dependent relationship 
between MS risk and the level of EBV specific antibodies, particularly 
EBNA-1 IgG titres. A key emerging feature is that it is important to examine 
not only the antibody titre but also the specificity of the humoral immune 
response to EBV and better understand what determines this. The evidence in 
relation to the presence or amount of EBV DNA in blood, CSF or brain is 
less clear, with studies presenting directly conflicting results. CD8 cytotoxic 
T cells maintain immunosurveillance and there is some evidence that there is 
dysfunction of these cells in MS. Such dysfunction should be accompanied 
by evidence of reactivation or higher EBV DNA load in cellular 
compartments but this has not been consistently shown. Table 2 summarizes 
the evidence on the role of EBV infection in the development of MS [102]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Summary of the level of evidence in relation to measures of EBV infection and MS 
risk (adapted from Lucas et al., J Neurol Neurosurg Psychiatry 2011). 
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1.4.3 Viral infections: other viruses 
 
Other viruses have been implicated as factors that may influence MS risk. 
These include, in addition to EBV, principally, human herpesvirus 6, Torque 
teno virus, varicella-zoster virus. The evidence for and against a role of most 
of these viruses in MS is inconsistent, except for that supporting EBV, as 
discussed above. 
 
Human herpesvirus-6 
 
Another ubiquitous herpesvirus that has gained relative popularity as 
potentially associated with MS is the human herpesvirus- 6 (HHV-6). It is 
characterized by phases of latency and reactivation that bear similarity to 
relapsing-remitting MS. The virus has neurotropic potential and was reported 
to infect oligodendrocytes and microglia cells, as well as to establish latency 
in CNS tissue which serves as a reservoir of persistent infection [131]. 
Another aspect that strengthens the hypothesized involvement of the virus in 
MS is the observation that primary HHV-6 infection may lead to severe 
neurological complications such as encephalitis and epilepsy. Besides being 
able to infect neural cell, HHV-6 most commonly establishes infection in T 
lymphocytes and supposedly exerts modulatory effects on the immune 
system [35]. Various studies in the past 15 years have investigated HHV-6 
association with MS. HHV-6 has been detected in serum, CSF as well as in 
brain tissue and more predominantly in MS lesions as reported by some 
studies [132; 133]. Besides direct cytopathic effect, other putative 
mechanisms of HHV-6 involvement in MS pathology include bystander 
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activation, and molecular mimicry. The later of which has gained compelling 
evidence. Myelin basic protein (MBP), a suspected target of autoreactivity in 
MS, has been determined to share sequence homology with HHV-6-encoded 
U24 protein. Cross-reactive T cells responding both to MBP and U24 
peptides were elevated in MS patients compared to controls [134]. So far, 
there is no epidemiological evidence that symptomatic HHV-6 infection 
increases the risk for development of MS and there is no data that would 
unequivocally support an etiologic role of HHV-6 in the pathogenesis of MS. 
However, the neuro- and lymphotropic potential of virus suggests that 
bystander reactivation of HHV-6 could potentially augment CNS 
inflammation [135]. 
 
Varicella zoster virus 
 
Varicella-zoster virus (VZV) is a ubiquitous pathogen that establishes latency 
in the dorsal ganglia in about 95% of adults. It is the causative agent of 
varicella (chickenpox), and can occasionally lead to symptomatic reactivation 
known as zoster [136]. Numerous epidemiological studies have investigated 
the link between VZV and MS, nevertheless, a meta-analysis including 40 
reports conducted between 1965-1999 revealed that there is insufficient 
evidence to support such association [137]. Presence of VZV DNA, however, 
has been reported in blood cells and CSF from relapsing MS patients [138]. 
Furthermore, Sotelo et al. observed electron microscopically abundance of 
viral particles identical to VZV in the CSF of MS patients during the initial 
days of disease relapse [139]. However, when Burgoon et al. used identical 
electron microscopic and PCR techniques they failed to identify presence of 
viral particles or DNA in MS CSF or acute MS plaques [140]. The weak 
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epidemiological data and the inconsistency in the observations render the link 
between VZV and MS elusive [38]. 
 
Torque teno virus 
 
Sospedra et al. determined the specificity of clonally expanded T cells from 
CSF of MS patients during exacerbation and observed that these T cell clones 
recognized evolutionary conserved arginine- rich motifs of functional protein 
domains of the orphan virus Torque teno virus (TTV) [141]. T cell clones 
resounded to TTV peptides as well as to peptides from other common viruses 
and selfantigens. Therefore, the authors speculated that repeated encounter, 
both of pathogenic or non-pathogenic infectious agents can lead to expansion 
of T cells responsive to conserved protein domains that are able to cross-react 
with ubiquitous self-antigens. These observations allude to the conclusion 
that recurrent infections with multitude of ubiquitous pathogens rather than 
one particular infectious agent could be implicated in the initiation of 
reactivity towards self-antigens that may trigger autoimmune pathologies. 
However, due to the paucity of data, the relation of TTV infection and MS 
remains ill defined [38].  
 
1.4.4 Parasitic infections 
 
Not only viruses and bacteria have been linked to MS, but also parasites. But 
helminths are thought to have a protective role in MS among other 
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autoimmune diseases [142]. The prevalence of helminth infections in 
countries with high sanitation standards has lead to the proposition of the 
hygiene hypothesis stating that regular exposure to various pathogens is 
required for the development of appropriate immune responses. 
Administration of helminths has been shown to ameliorate disease in a mouse 
model of MS [143]; while one clinical study has shown that when MS 
patients developed asymptomatic gastrointestinal infection, they experienced 
reduction of clinical and radiological MS activity, characterized by 
downmodulation of proinflammatory cytokines and increase in IL-10 and 
TGF-b production [144]. The long life span of helminths is evidence enough 
that they are well accomplished at immune evasion. Parasite infections are 
often asymptomatic, and most hosts tolerate the presence of parasites 
considered pathogens for considerable time periods without ill effects. 
Correale and collegues identified 12 parasite-infected MS patients that 
showed significantly lower number of relapses, minimal changes in disability 
scores and significantly lower MRI activity compared with uninfected MS 
individuals [144]. Parasite-driven protection was associated with induction of 
regulatory T cells secreting suppressive cytokines IL-10 and TGF-b, as well 
as CD4þ CD25þ FoxP3þ T cells displaying significant suppressive function. 
These findings provide evidence to support autoimmune down-regulation 
secondary to parasite infections in MS patients through regulatory T cell 
action, with effects extending beyond response to an invading agent. In 
addition to the development of regulatory T cells, helminth infections also 
induce regulatory B cells in MS patients, capable of dampening the immune 
response through production of IL-10 [145]. Interestingly, production of IL-
10 by B cells is restricted to helminth-infected individuals exclusively. B 
cells from patients with infections of other parasites such as Trypanosoma 
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cruzi exhibit IL-10 production levels similar to those observed in uninfected 
MS patients, indicating intracellular parasites are unable to down-modulate 
harmful autoimmune responses the way helminths do. Infectious agents may 
also down-modulate immune response through mechanisms not involving 
specific immune response induction against constituent antigens. Dendritic 
cells (DCs) express a range of pattern recognition receptors (PRRs), 
including Toll-like receptors (TLRs), nucleotide-binding oligomerization 
domainlike receptors (NLRs), retinoic acid-inducible gene-like receptors 
(RIG-like receptors) and the C-type lectin receptors (CLRs). Upon 
engagement, signaling cascades are initiated, inducing gene expression 
involved in DC maturation and in the ability to prime and skew T cell 
regulatory immune responses [146]. Another mechanism through which 
parasites affect host immunity, and ultimately concomitant disease also, is 
signaling-independent, and mediated by enzymatic activities of helminth-
derived products, which play an important role in establishing and 
maintaining infection through impairment of innate immune cell function 
[147]. Furthermore, a number of studies have documented the potent effects 
of cystatins, a class of molecules expressed by filarial nematodes, interfering 
with DC antigen presentation. Finally, helminth pathogens express cysteine 
proteases, termed cathepsines, which lead to immune deviation by 
suppressing Th1 immunity. Figure 12 summarizes all the potential 
mechanisms for immune regulation discussed above.  
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Figure 12 Summary of putative mechanisms through which helminths could modulate MS 
[149]. 
 
Each species can develop very different infection dynamics over time, and/or 
during peak infection intensity. Moreover, the same species may exert 
opposite effects under varying conditions. Finally, if susceptibility to 
autoimmune diseases is genetically influenced, so too must be the propensity 
for infections to modulate disease immunopathology, making particular 
infections protective only in certain genotypes, rather than in the whole 
population [148]. 
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1.5 Intestinal permeability and microbiota 
1.5.1 Hygiene hypothesis and gut microbiota  
 
Throughout the twentieth century, there were striking increases in the 
incidences of many chronic inflammatory disorders in the rich developed 
countries. These included autoimmune disorders such as Type 1 diabetes 
and multiple sclerosis. Although genetics and specific triggering 
mechanisms such as molecular mimicry and viruses are involved, a series 
of environmental factors, most of them microbial, have led to a decrease in 
the efficiency of our immunoregulatory mechanisms because we are in a 
state of evolved dependence on organisms with which we co-evolved as 
inducers of immunoregulatory circuits. The mammalian intestine hosts a 
large microbiota, which probably includes more than 103 different species. 
An equilibrium has been established, during the course of millennia of 
evolution, between the microbiota and the immune system, which is 
essential for immune homeostasis. However, epidemiological and clinical 
data describe a marked increase in the incidence of autoimmune and 
allergic disorders in western countries, where the reduced exposure to 
microbes, the wide-spread use of antibiotics and the major improvements 
in sanitation in general seem to correlate with a higher incidence of chronic 
autoimmune or allergic disorders. It is in fact possible that the delicate 
equilibrium between the microbiota and the immune system is perturbed by 
modern lifestyle, resulting in an imbalance between harmful and protective 
bacteria known as dysbiosis. All of these microrganisms will exacerbate 
the immunoregulatory deficit [149]. Figure 13 lists some relevant factors, 
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and also emphasizes the immunoregulatory role of the gut. One of the most 
important discoveries in recent years is the fact that manipulations of the 
immune system may act indirectly via changes in the gut flora. Consequent 
changes in the composition of the microbiota were responsible for the 
immunoregulatory effect that blocked the autoimmune process. Thus 
changes in the microbiota, which is profoundly different in Europeans from 
that of people living in a traditional rural African village must be regarded 
as part of the hygiene hypothesis[150].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Aspects of man’s microbiological history that are most relevant to the hygiene 
hypothesis. Epidemiological data, laboratory and animal models, and preliminary clinical 
trials investigating the hygiene hypothesis implicate organisms that are thought to have 
accompanied mammalian and human evolution. 
 
 
The hygiene hypothesis, or the “Old Friends” hypothesis, can be traced back 
to the 1870s when Charles Harrison Blackley noticed that aristocrats and 
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citydwellers were more likely to get hayfever than were farmers. Similarly, in 
1966, Leibowitz and colleagues noted that the incidence of multiple sclerosis 
in Israel was positively related to levels of sanitation [151]. The hygiene 
hypothesis suggests that one reason for the increasing incidences of chronic 
inflammatory disorders, (both Th2-mediated and Th1/Th17-mediated [152]), 
in developed countries since the mid-nineteenth century is the depletion from 
the urban environment of organisms that accompanied mammalian evolution 
and had to be tolerated. Some of these organisms had to be tolerated because 
they were essential symbiotic intestinal microbiota. Others, like helminths, 
had to be tolerated because once established they cannot be removed by the 
immune system, which is therefore downregulated to avoid pointless 
immunopathology. Other relevant organisms were species that established 
carrier states soon after birth. Because these all had to be tolerated, co-
evolutionary forces ensured that they came to play essential roles in the 
priming and optimal functioning of immunoregulatory pathways that are 
involved in tolerance [153]. Our knowledge of species and functional 
composition of the human gut microbiome is rapidly increasing, but it is still 
based on very few cohorts and little is known about variation across the 
world.  Arumugam and coworkers identified three robust clusters or 
enterotypes,  each identifiable by the variation in the levels of one of three 
genera: Bacteroides (enterotype 1), Prevotella (enterotype 2) and 
Ruminococcus (enterotype 3) (Fig. 14). Moreover they are not nation or 
continent specific demonstrating that intestinal microbiota variation is 
generally stratified and not continuous.  The robustness and predictability of 
the enterotypes in different cohorts and at multiple phylogenetic and 
functional levels indicates that they are the result of well-balanced, defined 
microbial community compositions of which only a limited number exist 
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across individuals. These enterotypes are not as sharply delimited as, for 
example, human blood groups; they are, in contrast, densely populated areas 
in a multidimensional space of community composition. They are 
nevertheless likely to characterize individuals, in line with previous reports 
that gut microbiota are quite stable in individuals and can even be restored 
after perturbation. The enterotypes are mostly driven by species composition, 
but abundant molecular functions are not necessarily provided by abundant 
species [154; 155; 156].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Phylogenetic differences between enterotypes (adapted from Arumugam et al., 
Nature 2011) 
 
 
The influence of the gut microbiota on human health is continuous from birth 
to old age. The maternal microbiota may influence both the intrauterine 
environment and the postnatal health of the fetus. At birth, about 100 
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microbial species populate the colon. Early environmental factors (e.g., 
method of delivery), nutritional factors (e.g., breast or bottle-feeding), and 
epigenetic factors have been implicated in the development of a healthy gut 
and its microbial symbionts. Changes in gut microbial composition in early 
life can influence risk for developing disease later in life. During suckling, 
the microbial community develops rapidly; shifts in microbial diversity occur 
throughout childhood and adult life; and in old age, there is a decrease in the 
Bacteroidetes and an increase in Firmicutes species. The gut microbiota is 
important for maintaining normal physiology and energy production 
throughout life. Body temperature regulation, reproduction, and tissue growth 
are energy-dependent processes thatmay rely in part on gut microbial energy 
production. Extrinsic environmental factors (such as antibiotic use, diet, 
stress, disease, and injury) and the mammalian host genome continually 
influence the diversity and function of the gut microbiota with implications 
for human health (Fig. 15) [157]. 
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Figure 15 The gut microbiota in development and disease [157] 
 
Additionally, the use of gnotobiotic mice, in which the presence and 
composition of the microbial composition is experimentally manipulated, has 
allowed for evaluation of specific microorganisms that may affect immune 
development. In particular, germ-free (GF) mouse experiments have led to 
great discoveries in autoimmune disease pathogenesis [158; 159]. The host 
mucosal immune system, particularly in the gut, works to protect the host 
from commensals and influences the make-up of the microbiome. After birth, 
the neonatal gut is colonized with maternal bacteria and ultimately forms a 
stable microbiotic profile. The mucosal immune system inhibits the entrance 
of intestinal bacteria through multiple mechanisms that include the epithelial 
barrier (e.g. mucus, tight junctions), antimicrobial peptides, mucosal IgA and 
innate and adaptive immunity. However, the containment of intestinal 
bacteria can be perturbed by environmental factors such as chemicals, tissue 
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injury (e.g. ischemia), and pathogenic infection [158; 159; 160; 161]. Defects 
in mucosal immunity allow bacteria to penetrate the epithelial barrier and 
induce inflammatory responses. If these defects or immune responses are not 
regulated, chronic inflammation can occur leading to a shift in the gut 
microbiome, often to a less diverse population of colonizing bacteria. 
Conversely, microbiota directly influence normal mucosal immune system 
development. GF mice have underdeveloped Peyer’s patches, mesenteric 
lymph nodes, and splenic white pulp  as well as defective formation of 
intestinal lymphoid follicles and decreased numbers of intestinal 
lymphocytes. These deficiencies can largely be corrected with the 
introduction of specific bacterial mixes, some single species, or bacterial 
products [158; 159; 161; 162; 163].  Investigation of MS 
immunopathogenesis has been greatly enabled by animal models, in 
particular that of the mouse experimental autoimmune encephalomyelitis 
(EAE) model. Berer and co-workers using the relapsing–remitting mouse 
model of spontaneously developing EAE, showed that the commensal gut 
flora—in the absence of pathogenic agents—is essential in triggering 
immune processes, leading to a relapsing–remitting autoimmune disease 
driven by myelin-specific CD4+ T cells. They showed further that 
recruitment and activation of autoantibody-producing B cells from the 
endogenous immune repertoire depends on availability of the target 
autoantigen, myelin oligodendrocyte glycoprotein (MOG), and commensal 
microbiota [164]. 
Microbiota also influence T cell subpopulations at steady state. Th17 cells, 
usually abundant in the gut, are absent in GF mice but can be restored with 
introduction of segmented filamentous bacteria (SFB) [158; 161; 163]. 
Regarding multiple sclerosis, although CD4
+
T lymphocytes are traditionally 
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considered the main actors in MS immunopathology, multiple evidences 
suggest that CD8+T lymphocytes are also implicated in the pathogenesis 
[165]. Recently, a significant expansion of CD161
hi
CD8
+ T cells in the 
peripheral blood of MS patients was described [166].  This subset includes 
CCR6
+
, cytokine-producing, effector-memory T cells with pro-
inflammatory profiles. It also contained all circulating IL-17
+
CD8
+ T cells. 
Moreover, CD161
+
CD8
+
CD3
+ T cells producing IFN-γ were part of 
intralesional immune infiltrates and ectopic B cell follicles in autopsy 
multiple sclerosis brains [167]. Finally, the CD161
hi
CD8
+
 
T subset proved 
to be positive for iVα7.2 TCR usage, thus overlapping with the mucosal-
associated invariant T (MAIT) cells. Human MAIT cells express the semi-
invariant TCR iVα7.2-Jα33 and are selected by the MHC class Ib molecule 
MR1 on hematopoietic cells. They are specifically activated by antigen 
presenting cells (APC) or epithelial cell lines co-cultured with bacteria or 
yeasts but not viruses. M o r e o v e r ,  MAIT cells include all the 
multidrug resistance transporter (ABCB1)
 +
CD161
hi
CD8
+ T cells, being 
probably resistant to the xenobiotics secreted by the gut bacteria. These 
features, together with their already known antimicrobial specificity, the gut-
liver homing characteristics, suggest a prevalent role in interact ion with 
intest inal microbiota [168]. Several reports indeed have started to point 
to dysbiosis as a major factor which influences the generation of 
proinflammatory rather than tolerogenic responses, with certain members 
of the microbiota such as Segmented Filamentous Bacteria inducing 
prominent pro-inflammatory Th17-mediated T cell responses, and other 
bacterial strains such as Clostridium facilitating the generation of 
immunosuppressive T regulatory lymphocytes [169; 170]. Interestingly, it 
was found that MAIT cells are in much lower numbers in subjects of rural 
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Zimbabwe in comparison with french blood donors [150]. At this stage it is 
not clear whether this decrease is genetically or environmental determined. 
The high number of MAIT cells found in MS patients would be a marker 
of low infection burden that would have favored autoimmunity in the 
context of the hygiene hypothesis. Alternatively, MAIT cells could be 
mechanistically implicated in MS pathogenesis, as suggested by recent 
works on the role of  gut microbiota in neuroinflammation. Stimulation of 
the immune system by bacteria can alter the outcome of demyelinating 
disorders in murine EAE, the widely accepted experimental model for 
human MS. Oral immunization with an attenuated Salmonella strain 
conferred protection against EAE as did the modification of bacterial 
populations in the gut. Bacteroides fragilis producing a bacterial capsular 
polysaccharide (PSA) can protect against EAE, via the induction of 
tolerogenic CD103
+
 dendritic cells, reduction of Th1 and Th17 responses, 
and enhancement of IL-10 production[171; 172]. The impact of microbiota 
on the balance between pro- and anti-inflammatory immune responses 
during EAE has been investigated by Mazmanian and colleagues: germ-
free animals were colonized with segmented filamentous bacteria, known 
to induce Th17 cells in the gut, and augmented Th17 responses could be 
measured not only in the colon and small intestine, but also in the spinal 
cord, underscoring the notion that the microbiota contains organisms that 
can direct proinflammatory immune responses in the CNS [173]. 
Bacteroides fragilis and PSA can also induce T regulatory cells (Tregs), that 
are decreased in the large intestine of GF mice [174].  These cells contribute 
significantly to the maintenance of peripheral tolerance, but they ultimately 
fail in autoimmune diseases. The events that lead to Treg failure in 
controlling autoreactive effector T cells (Teffs) during autoimmunity are not 
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completely understood. Many autoimmune diseases manifest themselves in 
an oscillating fashion, which is likely due to the aforementioned struggle 
between the regulatory and inflammatory arms of the immune system, 
suggesting that Tregs are still actively involved in regulating this self-reactive 
response. There are three mechanisms that might contribute to a breakdown 
in Treg control: (a) Treg numbers are reduced and/or Tregs are dysfunctional 
due to inherent deficiencies in autoimmune susceptible individuals, (b) Treg 
suppressive function is inhibited, diverted or converted by the chronic 
inflammation that occurs in autoimmunity, and/or (c) self-reactive effector T 
cells (Teff) become unusually aggressive and are refractory to regulation by 
otherwise functional Tregs because they either overwhelm regulatory control 
or express molecules that render them resistant. In EAE, Foxp3+ Tregs 
accumulate in the central nervous system (CNS) as the disease progresses 
and in some instances aid in natural recovery from EAE [175; 176; 177]. 
Moreover, CD4
+
FOXP3
+
 Treg cells are present most abundantly in the 
intestinal mucosa at steady state, and contribute to intestinal and systemic 
immune homeostasis. In germ-free mice, the frequency of colonic Treg cells 
and levels of IL-10 expression by Treg cells are markedly reduced [178; 179; 
180; 181; 182]. Atarashi et al. showed that a combination of Clostridia strains 
isolated from conventionally reared mice potently affect the number and 
function of CD41FOXP31 Treg cells in mouse colonic lamina propria4. 
Although a recent study showed that the human microbiota had no impact on 
the immune responses in the mouse small intestine, these findings suggest 
that the human intestinal microbiota contains Treg-cell-inducing bacteria 
[183]. 
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Altogether these data suggests the potential importance of intestinal 
microbiota on mucosal and intestinal immunity in the immunopathogenesis 
of autoimmune disease such as MS. 
 
1.5.2 Intestinal permeability and the zonulin system 
 
Regarding the immune system and in particular the mucosal immunity, 
gut-associated lymphoid tissue (GALT) , the neuroendocrine network and 
the intestinal epithelial barrier, with its intercellular tight junctions, 
controls the equilibrium between tolerance and immunity to non-self 
antigens. As mentioned in the previous paragraphs, the development of 
autoimmune diseases,  was believed that their  was associated with viral 
and bacterial infections. The connection between infection and 
autoimmune disease is often explained by a mechanism known as 
“molecular mimicry,” whereby microbial antigens are postulated to 
resemble self-antigens . The induction of an immune response to the 
microbial antigens results in a cross-reaction with the self-antigens and the 
induction of autoimmunity. According to this theory, once the autoimmune 
process is activated, it becomes independent of continuous exposure to the 
environmental trigger and is therefore self-perpetuating and irreversible 
[184]. Epitope-specific cross-reactivity between microbial antigens and 
self-antigens has been shown in some animal models to initiate 
autoimmunity. Conversely, in most human autoimmune diseases, 
molecular mimicry seems to be a factor in the progression of a pre-existing 
subclinical autoimmune response, rather than in the initiation of 
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autoimmunity [185]. Another theory suggests that microorganisms expose 
self-antigens to the immune system by directly damaging tissues during 
active infection, and that this leads to the development of autoimmunity. 
This mechanism has been referred to as the “bystander effect,” and it 
occurs only when the new antigen is presented with the orally administered 
triggering antigen. Whether pathogens mimic selfantigens, release 
sequestered self-antigens, or both, however, remains to be elucidated. A 
common denominator in autoimmune diseases is the presence of several 
pre-existing conditions that lead to an autoimmune process [186]. The first 
of these conditions is the genetic susceptibility of the host immune system 
to recognize, and potentially misinterpret, an environmental antigen 
presented within the gastrointestinal tract. The second is that the host must 
be exposed to the antigen. Finally, the antigen must be presented to the 
gastrointestinal mucosal immune system following its paracellular passage 
from the intestinal lumen to the gut submucosa; this process is normally 
prevented by competent TJ . In many cases, increased intestinal 
permeability seems to precede disease and causes an abnormality in 
antigen delivery that triggers the multiorgan process leading to the 
autoimmune response [187; 188]. Epithelial surfaces are immediately after 
birth coming into contact with numbers of micro-organisms. These 
surfaces therefore evolved a number of protective mechanisms to resist the 
invasion of micro-organisms. In particular, gastrointestinal surface is 
mostly covered with a single-layered epithelium and require, therefore, a 
more extensive protection: this is represented by a complex of mechanical 
and chemical agents responsible for effective degradation and removal of 
heterogeneous substances [189]. The primary functions of the 
gastrointestinal tract have traditionally been perceived to be limited to the 
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digestion and absorption of nutrients and to electrolytes and water 
homeostasis. A more attentive analysis of the anatomic and functional 
arrangement of the gastrointestinal tract, however, suggests that another 
extremely important function of this organ is its ability to regulate the 
trafficking of macromolecules between the environment and the host 
through a barrier mechanism. Together with the gut-associated lymphoid 
tissue and the neuroendocrine network, the intestinal epithelial barrier, 
with its intercellular tight junctions, controls the equilibrium between 
tolerance and immunity to non-self antigens [190]. The intestinal 
epithelium consists of a layer of interconnected, polarised epithelial cells 
separated by a basal membrane from the connective and supporting tissue 
surrounding various types of cells present in the lamina propria. Normally, 
antigens are selectively sampled by intestinal M cells which are modified 
epithelial cells specially designed for the endocytosis of luminal antigens 
[191]. Than, the antigens are displayed to antigen presenting cells, such as 
macrophages, where they are degraded and incorporated into an antigen 
presenting protein complex termed the major histocompatability complex 
(MHC) or human leukocyte antigen (HLA). From here, down stream T and 
B cell activation will occur, which will ultimately result in the production 
of chemical mediators to elicit an immune response. Despite this, some 
macromolecules have shown the ability to cross the intestinal epithelium 
without M cell passage. This can occur transcellularly, where antigens are 
absorbed directly through epithelial cells or  through (Fig. 16 ) [192]. 
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Figure 16 Intestinal barrierer as modulator of intestinal homeostasis (Natividad&Verdu, 
Pharm. Res., 2012) 
 
The paracellular route that is the dominant pathway for passive solute flow 
across the intestinal epithelial barrier, and its functional state depends on 
the regulation of the intercellular TJ [193]. The TJ is one of the hallmarks 
of absorptive and secretory epithelia. As a barrier between apical and 
basolateral compartments, it selectively regulates the passive diffusion of 
ions and small water-soluble solutes through the paracellular pathway, 
thereby compensating for any gradients generated by transcellular 
pathways [194]. TJ are structures dynamic and readily adapt to a variety of 
developmental [195], physiological [196], and pathological [197; 198] 
circumstances. To meet the diverse physiological challenges to which the 
intestinal epithelial barrier is subjected, TJ must be capable of rapid and 
coordinated responses. This requires the presence of a complex regulatory 
system that orchestrates the state of assembly of the TJ multiprotein 
network. The molecules forming tight junctions (principally occludins and 
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claudins) are connected to the cytoskeleton of epithelial cells. In addition 
to laterally situated tight junctions present in zonula occludens, there are 
intermediary junctions and desmosomes in the so-called zonula adherens 
(Fig. 17). While knowledge about TJ ultrastructure and intracellular 
signaling events has progressed significantly during the past decade, only 
recently we have seen effort focused on elucidating the link between TJs 
and many pathophysiological states [186; 199] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Structure of intestinal epithelial barrier ((Natividad&Verdu, Pharm. Res., 2012). 
 
Zonulin is the only physiological modulator of intercellular tight junctions 
described so far that is involved in trafficking of macromolecules and, 
therefore, in tolerance/immune response balance. When the finely tuned 
zonulin pathway is deregulated in genetically susceptible individuals, both 
intestinal and extraintestinal autoimmune, inflammatory, and neoplastic 
disorders can occur. This new paradigm subverts traditional theories 
underlying the development of these diseases and suggests that these 
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processes can be arrested if the interplay between genes and environmental 
triggers is prevented by reestablishing the zonulin-dependent intestinal 
barrier function. Zonulin is an human homolog of Zot (zonula occludens 
toxin), an enterotoxin elaborated by Vibrio cholerae that affects the TJ 
competency, has shed light on the intricate mechanisms involved in the 
modulation of the intestinal paracellular pathway [190].  Zonulin expression 
is augmented in autoimmune conditions associated with TJ dysfunction, 
including celiac disease (CD) and T1D. Both animal studies and human trials 
using the zonulin synthetic peptide inhibitor AT1001 (now named Larazotide 
acetate) have established that zonulin is integrally involved in the 
pathogenesis of autoimmune diseases. Zonulin can be used as a biomarker of 
impaired gut barrier function for several autoimmune, neurodegenerative, and 
tumoral diseases and can be a potential therapeutic target for the treatment of 
these devastating conditions [200; 201; 202; 203]. 
Zonulin was recently identified, through proteomic analysis of human sera, 
as pre-haptoglobin (HP) 2, a molecule that, to date, has only been regarded 
as the inactive precursor for HP2, one of the two genetic variants (together 
with HP1) of human HPs. Mature human HPs are heterodimeric plasma 
glycoproteins that form stable complexes with haemoglobin (HB) 
preventing Hb-induced oxidative tissue damage [204; 205].  
Conversely, zonulin is detectable in an uncleaved form in human serum, 
adding another extremely intriguing aspect of the multifunctional 
characteristics of HPs. HPs are unusual secretory proteins in that they are 
proteolytically processed in the endoplasmic reticulum, the subcellular 
fraction in which we detected the highest zonulin concentration [206]. 
Wicher and Fries found that the complement C1r-like protein mediates this 
cleavage in a specific manner, since the enzyme did not cleave the proform 
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of complement C1s, a protein similar to Pre-HP2. Therefore, it is 
conceivable to hypothesize that the activity of Cr-like protein modulates 
the zonulin pool [206]. Zonulin interacts with a specific surface receptor 
whose distribution within the intestine varies. The protein then activates 
phospholipase C that hydrolyzes phosphatidyl inositol to release inositol 
1,4,5-tris phosphate (PPI-3) and diacylglycerol (DAG). PKCα is then 
activated, either directly (via DAG) [4] or through the release of 
intracellular Ca2+ (via PPI-3) [185; 187; 188]. Membrane-associated, 
activated PKCα catalyzes the phosphorylation of target protein(s), with 
subsequent polymerization of soluble G-actin in F-actin. This 
polymerization causes the rearrangement of the filaments of actin and the 
subsequent displacement of proteins (including ZO-1) from the junctional 
complex [206]. As a result, intestinal TJ becomes looser. Once the zonulin 
signaling is over, the TJs resume their baseline steady state (Fig. 18) 
 
 
 
 
 
 
 
 
 
 
Figure 18 The zonulin signalling [184]. 
Among the several potential intestinal luminal stimuli that can trigger 
zonulin release, we identified small intestinal exposure to bacteria and 
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gluten as the two more powerful triggers. Enteric infections have been 
implicated in the pathogenesis of several pathological conditions, including 
allergic, autoimmune, and inflammatory diseases, by causing impairment 
of the intestinal barrier. We have generated evidence that small intestines 
exposed to enteric bacteria secreted zonulin. This secretion was 
independent of either the animal species from which the small intestines 
were isolated or the virulence of the microorganisms tested, occurred only 
on the luminal aspect of the bacteria-exposed small intestinal mucosa, and 
was followed by an increase in intestinal permeability coincident with the 
disengagement of the protein ZO-1 from the tight junctional complex 
[208]. This zonulin-driven opening of the paracellular pathway may 
represent a defensive mechanism which flushes out microorganisms so 
contributing to the innate immune response of the host against bacterial 
colonization of the small intestine. In addition to bacterial exposure, it was 
shown that gliadin also affects the intestinal barrier function by releasing 
zonulin. This effect of gliadin is polarized, i.e., gliadin increases intestinal 
permeability only when administered on the luminal side of the intestinal 
tissue [209]. Concerning multiple sclerosis, in addition to an increase in 
blood-brain barrier permeability in multiple sclerosis (MS) patients may 
also experience an increased permeability of intestinal TJ [210; 211]. 
Yacyshyn et al. have demonstrated that 25% of MS patients studied had an 
increased intestinal permeability. The fact that patients with MS (and 
Crohn’s disease both present an increased number of peripheral B cells 
exhibiting CD45RO, a marker of antigen exposure, further supports the 
concept of preexisting, genetically determined small intestinal permeability 
abnormalities with subsequent altered antigen exposure as a pathogenic 
factor common to these diseases [212; 213]. To challenge this hypothesis, 
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Fasano e coworkers measured serum levels of zonulin in MS patients with 
different subtypes—relapsing–remitting [RRMS] vs. secondary–
progressive [SPMS]—and activities to ascertain whether expression of 
zonulin into peripheral circulation can differentiate these two groups. 
Approximately  29% of patients with either RRMS or SPMS had elevated 
serum zonulin levels with overall average serum levels ~2.0-fold higher 
than in controls. Interestingly, patients with RRMS in remission showed 
serum zonulin levels comparable to controls [190]. 
 
1.5.3 MRP8/14 
Calprotectin (MRP8/14, S100A8/S100A9, 27E10 antigen) is a heterodimer 
of two calcium-binding proteins present in the cytoplasm of neutrophils 
and expressed on the membrane of monocytes. Upon neutrophil activation 
or endothelial adhesion of monocytes, calprotectin is released and may be 
detected in serum or body fluids as potentially useful clinical inflammatory 
marker. The soluble form of calprotectin provides both bacteriostatic and 
cytokine-like effects in the local environment. Calprotectin was originally 
discovered as an antimicrobial protein that was present in the cytoplasm of 
neutrophil granulocytes but it is absent in mature limphocytes [214; 215]. 
Subsequently, it has been recognized as a promising marker of 
inflammation, or rather a trace of the antagonism going on inside the 
organism [216]. Furthermore, the molecule is involved in the recruitment 
of inflammatory cells by interactions with endothelial cells and its zinc 
capturing function may affect physiological homeostasis [217]. The 
pleiotropic functions of calprotectin are associated mostly with active 
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inflammatory processes including antibacterial defense mechanisms or 
with Th1-mediated responses such as allograft rejection or in autoimmune 
reactions. It is a 24 kD heterodimer composed of light (MRP8) and heavy 
(MRP14) chains (8 and 14 kDa), members of the S-100 family of calcium-
binding proteins [218; 219]. The binding of calcium induces 
conformational changes, the calcium-saturated state, which allows binding 
of other proteins. In the presence of calcium, MRP8/14 heterodimeric 
complexes may tetramerize into heterotetramers [220]. Calprotectin also 
contains zinc-binding domains, which have a zinc-binding capacity higher 
than other S100 proteins, and are not affected by the binding of calcium. 
Both MRP8 and MRP14 contain histidine-based zincbinding sequences 
(His-X-X-X-His motif), which are involved in the antibacterial activity of 
calprotectin [221]. Calprotectin was originally found in neutrophils and a 
subpopulation of mononuclear phagocytes. Its concentration is abundant 
and constitutes about half of total cytosolic protein. Calprotectin is secreted 
extracellularly from stimulated neutrophils and monocytes, or is released 
as a result of cell disruption or death [222; 223]. After cell death, 
calprotectin is released into pus or abscess fluid together with microbicidal 
nucleohistones. The soluble form of calprotectin is found in serum, urine, 
body secretions (higher calprotectin levels were found in saliva of subjects 
with candidiasis, and the calprotectin concentration correlated positively 
with the severity of candidal infection), intestinal fluid and feces [224].  
It has been shown that the concentration of the heterodimer MRP8/14 in 
serum is a marker for acute inflammation and it has been related to disease 
activity in inflammatory diseases like colitis ulcerosa and rheumatoid 
arthritis [225]. Regarding multiple sclerosis, as described previously, this 
disease is characterized by the presence of sclerotic lesions or plaques, 
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scattered throughout the brain [226]. Early events in the development of 
these lesions are the increase of blood-brain barrier (BBB) permeability 
and the formation of cellular infiltrates (monocytes and lymphocytes) 
[227].  Demyelination is characterized by the presence of myelin 
degradation products within macrophages and by the expression of 
macrophage differentiation markers (MRPs) such as MRP8 that is equally 
distributed throughout the lesion whereas MRP14 and the heterodimer 
MRP8/14 are mainly present in active demyelinating lesions. Indeed, 
Bogumil and collegues found elevated serum levels of MRP8/14 in MS 
patients during a relapse compared to patients in remission [228]. 
Furthermore, in vitro studies suggested an important role of calprotectin in 
extravasation of leukocytes by the attachment to endothelial cells via the 
MRP-14 subunit interacting mainly with endothelial heparan sulfate 
proteoglycans [229]. Calprotectin binding to microvascular endothelial 
cells may also be induced by arachidonic acid [230]. The signalling 
pathways of calprotectin are not fully elucidated, but involve MAP kinase 
cascade activation [231]. The interaction of monocytic calprotectin with 
activated endothelium leads to its release, which may account for the high 
calprotectin concentrations in the body fluids of patients with acute or 
chronic inflammatory diseases [232]. Released calprotectin may be 
involved in inflammation by enhancing CD11b expression in human 
monocytes and by participating in the transendothelial migration 
mechanism [233]. Calprotectin also inhibits the microbial growth through 
competition for zinc. Zinc chelation that is mediated by histidine-rich 
regions of calprotectin represents an important antimicrobial mechanism in 
host defense [221]. The upregulation of serum calprotectin levels may 
occur in different immune and immunopathological reactions, especially in 
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acute inflammation or Th1- mediated responses. In some respects, the 
sensitivity and dynamics of calprotectin seem to overcome traditional 
inflammatory markers such as C-reactive protein (CRP). There are several 
lines of evidence showing the importance of calprotectin in defense 
mechanisms and physiological functions of the immune system. The 
clinical usefulness of calprotectin as an inflammatory marker has been 
shown not only in gastroenterology, where determination of the protein in 
feces is a noninvasive parameter reflecting pathological processes going on 
in the mucosa. The serum level of calprotectin may be a very sensitive 
non-specific flamnmatory marker in various clinical settings [234].                                                                                                                                     
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Chapter 2: Aim of the study 
 
Multiple sclerosis (MS) is an inflammatory, autoimmune disease of the 
central nervous system (CNS) in which an interplay of genetic and 
environmental factors leads to the chronic activation of immune cells and to 
neuronal injury. Epidemiological studies have identified several non-heritable 
risk factors in MS, including viruses, vitamin D and sun exposure, smoke, 
diet and many others. All these factors  may be associated  with both disease 
susceptibility and  disease course [38; 45; 53; 84]. To explain the significant 
increase of autoimmune diseases in western societies in recent decades, the 
‘hygiene hypothesis’ speculates that modern life styles and widespread use of 
antibiotics have reduced the exposure of humans to microbes. This decreased 
microbial load contrasts with the situation  in developing  countries  where 
exposure to microbes is high and prevalence of autoimmune disease is low 
[149]. This work is in the context of our long-lasting in-depth study of the 
relationship between microbes and MS. In particular this thesis is focused on 
the study of Epstein Barr virus (EBV) genotypes and  the evaluation of  gut 
epithelium permeability in MS.  
Among the non-heritable causative factors potentially involved in the MS 
etiology, EBV received the most convincing evidence. Nonetheless, it is 
difficult to understand how a virus that ubiquitously infects humans can be 
associated with a disease of relative limited prevalence. The possibility that 
only a particular viral genotype associates with the disease is plausible and 
has been investigated in this project. We studied EBV genomic variants in B 
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cells of MS patients and healthy controls and tried to disclos whether a single 
or several genomic variants of EBV are specifically associated to MS and 
may help to clarify the role of a plausible etiologic factor, such as EBV.  
With regard to a possible  involvement  of the gut flora in MS pathogenesis 
recent works show that the commensal gut flora, in the absence of pathogenic 
agents, is essential in triggering immune processes, leading to develope 
experimental autoimmune encephalomyelitis (EAE) driven by myelin-
specific CD4+ T cells in a mouse model. The same work showed further that 
recruitment and activation of autoantibody-producing B cells from the 
endogenous immune repertoire depends on availability of the target 
autoantigen, myelin oligodendrocyte glycoprotein (MOG), and commensal 
microbiota [164]. Furthermore, Annibali and co-workers recently reported 
the potential pathogenic relevance of a proinflammatory CD161hiCD8+ T 
cell subset that was increased in the peripheral blood of patients compared to 
controls and detectable in post- mortem MS lesions [166]. The same group, 
by analyzing the T cell receptor (TCR) usage of CD161hiCD8+ T cells, 
found that this subset largely overlapped with the mucosal-associated 
invariant T (MAIT) cells, that have been recently characterized as 
antibacterial, gut-homing CD161hi T cells. The MAIT cells have been shown 
to contain the entire CD8+ T cell subset able to secrete IL-17. Th17 cells 
implication has been suggested in the pathogenesis of MS [168]. 
Alterations in the composition of the gut flora  could affect the intestinal 
mucosa and inappropriately activate the immune system. Thus an altered 
physiology and/or immune function of gut mucosa may impact intestinal 
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permeability, especially leading to an increase of epithelial paracellular 
space. A change in intestinal permeability may be considered a biomarker of 
local or even distant immune-mediated disorders. In fact increased gut 
permeability allows the passage, through the intestinal epithelial layer, of 
macromolecules, toxin, and bacterial species, both pathogenic and 
commensal, that may trigger immune-mediated illnesses in different systems, 
even distant from the gastrointestinal tract. 
Another aim of this project is verifying the hypothesis that dysfunction of gut 
permeability and unbalance of intestinal microbiota may contribute to MS 
immunopathogenesis. For this part of the project,  we will  study  the 
intestinal permeability in MS patients and healthy donors through the 
evaluation of lactulose-mannitol ratio in urine. Moreover, intestinal 
dysfunction will be also studied  by different serum biomarkers, such as 
zonulin and  calprotectin, whose  role  has been recently recognized. 
Zonulin modulates the tight junctions, multiproteic structures that regulate 
the para-cellular spaces between epithelial cells [188]. In autoimmune 
disorders associated with a dysfunction of intestinal permeability, such as 
celiac disease and type1 diabetes, an higher expression of zonulin 
correlates with increased levels of intestinal permeability [184]. Being the 
zonulin system active only in the small intestine, we chose to consider also  
the calprotectin which is a good marker of altered permeability and 
inflammation in the colon. Calprotectin is a heterodimer consisting of two 
calcium binding proteins, MRP8 and MRP14 (myeloid related proteins), 
that was found to be elevated in active MS lesions [228]. 
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Chapter 3: Materials and methods 
 
3.1 Analysis of EBV genotypes: EBNA2 single 
nucleotide polimorphisms 
 
Patients and matched (age-sex and geographic origin) healthy donors (HD) 
were blood sampled and imaged at the same time point with gadolinium-
enhanced magnetic resonance imaging (MRI). The local Institutional Review 
Board approved the study and all participating subjects gave written informed 
consent. All patients were free from therapy at the time of sampling. 
Peripheral blood mononuclear cells (PBMCs) were obtained by density 
centrifugation over Ficoll–Hypaque according to standard procedure. The 
cells were stained with anti-human CD19 antibodies (Miltenyi Biotec) and 
separated by magnetic beads in accordance with the manufacturer’s 
recommended protocol.  
Genomic DNA was extracted from PBMCs, CD19+ B cells and cell lines 
(B95-8 EBV-positive cell line and BJAB EBV-negative cell line) by 
commercially available kit (QIAamp DNA mini kit, Qiagen).  
All samples were analyzed by a semi-nested PCR approach using EBNA2 
type specific primers
 
(ref. thierney).  All PCR products were assayed by 
sequence analysis. The sequences were aligned with ClustalW2 multiple 
sequence alignment program (www.ebi.ac.uk/Tools/msa/clustalw2/) and the 
variants were considered when there was a deviation from the published 
B95.8 (NCBI accession number V01555) EBV prototype.
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 3.2 Evaluation of intestinal permeability and 
serological markers of intestinal inflammation  
 
Blood and urine samples were obtained from RRMS patients and healthy 
matched for age, sex, ethnicity and geographic origin. The patients, followed 
at Centre for Experimental Neurological Therapies [(CENTERS), S. Andrea 
Hospital Site, Sapienza University of Rome, Italy], were free of disease- 
modifying therapies. The local Institutional Review Board approved the 
study and all participating subjects gave written informed consent.  
 
Intestinal permeability test: intestinal permeability  will be evaluated through 
a test based on the assumption of an oral solution of lactulose and mannitol 
and subsequent measurement of their intestinal absorption evaluating the 
urinary excretion in the 5 hours after the start of the test. After collecting a 
pre-test urine sample, the subjects will take 50ml of a solution of 5 g of 
lactulose and 2 g of mannitol dissolved in deionized water. After one hour the 
subjects will be encouraged to drink water. The urine will be collected during 
the next 5 hours: the total volume of urine will be measured and a sample of 
10 ml will be stored at -20 °C until the assay will be performed. The urine 
concentrations of lactulose and mannitol will be measured using a method 
based on liquid chromatography combined with mass spectrometry [234]. 
All participants will follow a lactose-, lactulose-, mannitol- free diet for 72 h 
before the test. A list of forbidden food will be provided. 
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Serological dosage of zonulin: In order to obtain the serum, the whole blood 
sample was centrifuged at 3000rpm for 10 minutes. The dosage of zonulin 
was performed through the use of a specific Enzyme-linked immunosorbent 
(ELISA) assay commercially available kit (Zonulin Elisa,  Immundiagnostik) 
according to the protocol of the manufacturer.  
 
MRP8/14 (calprotectin) dosage: In order to obtain the serum, the whole 
blood sample was centrifuged at 3000rpm for 10 minutes. Serum MRP8/14 
was dosed using a specific ELISA commercially available kit (PhiCal 
Calprotectin (MRP8/14) ELISA, Immundiagnostik), according to the 
protocol of the manufacturer.  
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Chapter 4: Results 
 
4.1 Epstein Barr virus genomic variants 
 
We obtained blood samples from 58 patients and 49 matched (age, sex, 
ethnicity and geographic origin) HD. The rate of successful EBNA2 
genotyping was comparable between the two groups: 39/58 (67.2%) in 
patients and 33/49 in the HD (67.4%). The 39 patients with a successful 
genotyping had a relapsing-remitting form of disease (7 were under disease 
modifying therapies and the others were treatment naïve). The mean age was 
34.8±8.6 in the patients and 36.52±9.5 in the HD; the male/female ratio was 
9/30 in the patients 10/23 in the controls. Seven patients and three HD were 
analyzed at different time points (from one to twelve months apart): two 
patients and one HD were infected by different strains (1.2, 1.3B, GD1) at 
different time points, while the EBV subtype remained the same in the 
remaining subjects (Table 3). Taking into account each sampling as an 
independent observation, we analyzed a total of 89 blood samples (52 in MS 
patients and 37 in HD).  
We observed a significant bias in the distribution of EBV subtypes (Table 
3A): the 1.2 allele was predominant in patients (29/52 vs 8/37, p=0.002), 
while the 1.3B allele prevailed in controls (24/37 vs 14/52, p=0.0005). 
Gender did not appear to modify this distribution (Table 3B). Going beyond 
the variants that are encompassed by B95.8 coordinates 48959–49208 [235] 
our analysis identified other previously undetected divergences from the 
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EBV wt strain at the amino acids 134, 236, 245, 256 and 267 (Table 5; Table 
4A). While the change at position 256 (D/N) was present in subtypes 1.2, 
1.3B and GD1, without differences between patients and controls, the other 
four variants proved to be associated with the 1.2 subtype and consequently 
correlated with MS status (Table 5; Table 4B). Interestingly, when comparing 
only patients and HD infected by 1.2 EBV subtype (Table 4C) the 
divergences at position 245 (P/S or P/T) were more frequent in the patients 
(21/29 [72.4%] vs 3/8 [37.5%], p=0.04); moreover, the co-occurrence of the 
four 1.2 subtype-related variants was significantly higher in the patients than 
in the HD (18/29 [62%] vs 2/8 [25%], p=0.04). 
We found no correlation between EBV genotypes and clinical characteristics 
of patients (MRI data, expanded disability status scale, disease duration). 
When we analyzed samples from single time points in the population with 
stable EBV infection (37 MS patients and 32 HD), we obtained comparable 
results in the EBV subtypes and variants distribution, as well as in the 
potential to predict MS status (not shown). 
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Table 3: Frequency of subtypes of EBNA2 in the peripheral blood of MS 
and HD: global data (A) and results separated by gender (B). 
 
EBNA2 = Epstein Barr Nuclear Antigen 2; aa = aminoacids; MS = Multiple 
Sclerosis; HD = healthy donors;  ns = not significant. 
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Table 4: Frequency of aa variants of EBNA2 (A) and their different 
combinations (B) in MS patients and HD; frequency of variants in patients 
and HD infected by subtype 1.2 (C)  
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EBNA2 = Epstein Barr Nuclear Antigen 2; aa = aminoacids; MS = Multiple 
Sclerosis; HD = healthy donors;  ns = not significant. 
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Table 5: nucleotide and amino acid substitutions within the sequence 
EBNA2 compared to the genomes of type 1 B95-8 and GD1 
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INS = aminoacid insertion; HD = healthy donors; MS = multiple sclerosis 
patients. 
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4.2 Evaluation of intestinal permeability  
 
We obtained urine samples from 18 multiple sclerosis patients and 16 
matched (age, sex, ethnicity and geographic origin) HD. All patients had a 
relapsing-remitting form of disease and they were free from therapy at the 
moment of the sampling. The mean age was 37.4±10.6 in the patients and 
36.8±10.1 in the HD; the male/female ratio was 6/12 in the patients 2/14 in 
the controls. 
We observed that MS patients show an increase of intestinal permeability 
compared than healthy controls (p value=0.039 Mann Whitney test) (Fig 19).   
 
 
Figure 19 Evaluation of intestinal permeability by lactulose (Lac)/mannitol (Man) 
concentration in urine in MS patients and healthy controls 
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Furthermore we observed that MS patients show a lower urinary mannitol 
concentration (p value=0.033 Mann Whitney test)  (Fig 20).  
We found no correlation between these alterations and clinical characteristics 
of patients (MRI data, expanded disability status scale, disease duration). 
 
 
Figure 20 Urinary concentration of mannitol in MS patients and healthy controls 
 
 
4.3 Evaluation of gastrointestinal inflammation 
biomarker: zonulin and calprotectin  
 
Concerning the analysis of serum levels of zonulin, we analyzed serum 
samples from 15 MS patients and 12 matched (age, sex, ethnicity and 
geographic origin) HD. All patients had a relapsing-remitting form of disease 
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and they were in remission at the moment of the sampling. Furthermore, all 
subjects (MS and HD) were free from antibiotics treatment and other 
therapies at the moment of the sampling. The mean age was 35.5±9.7 in the 
patients and 35.5±10.7 in the HD; the male/female ratio was 4/11 in the 
patients 1/11 in the controls. 
As shown in the figure, we didn’t observe any difference in the serum 
concentrations of this biomarker between MS patients and HD (p value= 
0.102 Mann Whitney test) (Fig.21) 
 
 
Figure 21 Serum zonulin in MS patients and healrhy donors 
 
With regard to the analysis of the serum calprotectin (MRP8/14) we obtained 
serum samples from 10 multiple sclerosis patients and 7 matched (age, sex, 
ethnicity and geographic origin) HD. All patients had a relapsing-remitting 
form of disease and they were free from therapy at the moment of the 
92 
 
sampling. The mean age was 34.1±8.8 in the patients and 37.5± 11.2 in the 
HD; the male/female ratio was 3/7 in the patients 1/6 in the controls.  
Also in this case we didn’t observe any difference in the serum 
concentrations of the biomarker between patients and healthy controls (p 
value= 0.845 Mann Whitney test) (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Serum calprotectin (MRP8/14) in MS patients and healrhy donors 
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Chapter 5: Conclusions, discussions and 
future perspectives 
 
Similar to other common autoimmune diseases, predisposition to multiple 
sclerosis (MS) is conveyed by immune system associated genes and by non 
heritable factors. The role of environmental risk factors such as infections, 
lack of vitamin D, smoking, diet and their interaction with genetic 
susceptibility alleles are much less well defined, despite the fact that 
infections and non-infectious factors have long been associated with MS 
development. 
Concerning the first part of the project, dedicated to the study of EBV, the 
results obtained show that the MS status correlates with an excess of 
EBNA2 1.2 and a paucity of 1.3B subtypes. Moreover, patients are more 
likely to harbor the newly identified 1.2 subtype-related variants 
(particularly the one at amino acid position 245). Previous studies on a 
possible association between EBV genotypes and MS gave mixed results: 
no association with EBNA6, EBNA1 and LMP1, EBNA2;  “marginally 
different frequencies” for BRRF2 and EBNA1; more frequent EBNA2 type 
1 and 2 co-infection in patients than in healthy subjects [236; 237; 238; 
239; 240; 241]. On a region of EBNA2, that previous studies did not 
investigate, we find genotypes with associations that are stronger than 
those previously reported including EBNA2 subtypes and EBNA2 newly 
detected polymorphisms. Apart from the predictive potential of EBNA2 
variants, the likelihood that they may carry functional consequences that 
underlie contribution to disease etiology deserves further consideration. In 
a virus not prone to mutations, new variants are more likely to have some 
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functional impact. There are only two major types of EBV (types 1 and 2), 
which appear to be identical over the bulk of the genome but show allelic 
polymorphism in a subset of latent genes: EBNA-LP, EBNA2, EBNA3A, 
EBNA3B and EBNA3C. In particular, the two EBV types share 64% of the 
nucleotide and 53% of the predicted amino acid sequences of EBNA2 and 
EBNA2 sequence mutations are indeed able to affect their interaction with 
other host proteins [242; 243]. We studied the most polymorphic region of 
EBNA2, where the sequence divergence between type 1 and type 2 resides. 
These differences may have functional consequences, also of 
immunological relevance [244;245]. Moreover this region is involved in 
interactions with cellular proteins such as Nur77 and SMARCB1 that have 
been associated with multiple sclerosis and antiviral responses [246; 247; 
247; 248; 249; 250]. The association between viral variants and immune-
mediated pathology is certainly not new. Our work suggests that this may 
be the case also for MS, through variants that may have a functional impact 
on the host. The EBNA2 region that we have investigated is a first 
objective on which to concentrate further study, and we cannot exclude 
that additional regions of the complex EBV genome may be relevant as 
well.  Furthermore, these results may help to define the subjects 'at risk' or 
help clinicians in the diagnosis and prognosis of the disease. In addition, 
the identified gene variants might be considered as a therapeutic target for 
possible preventive strategies. 
In the light of these findings and those obtained from recent GWAS 
(Genome Wide Association Studies) studies conducted on MS [20], our 
research group has proposed a new analysis, a ‘‘candidate interactome’’ 
(i.e. a group of genes whose products are known to physically interact with 
environmental factors that may be relevant for disease pathogenesis) 
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analysis of genome-wide association data in MS, to further understand the 
gene-environment interaction that is crucial for interpreting the relevance 
of non-heritable factors and prevents from overlooking genetic associations 
with small but measurable effects. We elected to center the analysis on 
viral interactomes but we also analyzed interactomes of other elements that 
may still be potentially relevant in gene-environment interactions 
associated with multiple sclerosis (for example human innate immunity 
interactome for type I interferon and vitamin D receptor). Three 
interactomes show a statistical enrichment of associations and the EBV 
interactome is among these. The absence of associations with the 
interactomes of phylogenetically related viruses (CMV and HHV8, both 
herpesviruses with the latter that shares the same site of latency as EBV) 
reinforces the specificity of the EBV result. With regard to EBV, the 
results obtained from the analysis of the interactome and the study of 
genotypes suggest a model of the genetic puzzle, so both host and virus 
polymorphisms influence susceptibility to MS and, through complex 
epistatic interactions may lead to the development of diseases [251; see 
Attachments]. 
The second part of the project focused on the role of intestinal permeability 
(IP) in MS. We observed that MS patients show altered values of IP 
compared to healthy controls. The result, though significant,  does not 
allow  to say  that  permeability changes of the intestinal epithelium are 
involved in MS pathogenesis ..To clarify the possible immunopathogenic 
role of alterations in intestinal permeability it will be necessary to increase 
the sample size of the  study population and to try to correlate results on IP 
with those coming from other ongoing studies on gut microbiota and 
mucosal lymphocyte subsets in MS.  
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The observation that MS patients show a lower concentration of mannitol 
in the urine may be indicative of a reduced absorbing surface (mannitol is 
absorbed through the paracellular intestinal intake, being its urinary 
concentration  proportional to the surface of intestinal absorption). 
Interestingly, this data is also found in patients who did not show an 
increase in intestinal permeability (IP is expressed as the ratio of two 
concentrations, and this value does not take into account the absolute value 
of the single concentrations of the two sugars ). This result might help to 
understand eventual individual variability in the clinical response to the 
new oral therapies in MS. Recent clinical research in multiple sclerosis was 
especially aimed at the development of oral drugs such as fingolimod, 
teriflunomide, and fumarate. Several clinical trials demonstrated 
therapeutic efficacy of these drugs in patients with RRMS and an 
acceptable safety profile. However,  common side effects in the 
gastrointestinal tract occur (and among these are frequent episodes of 
diarrhoea;  suggesting that a better understanding of  intestinal 
dysfunctions in MS may help  to deepen  mechanisms of action and to 
increase  therapeutic index of the new oral drugs [252].  
To complete the study on intestinal dysfunction in MS, we analyzed in the 
sera of patients and healthy controls, two markers of intestinal 
inflammation: zonulin, a key regulator of intercellular tight junctions and 
MRP8/14 (calprotectin), a myeloid related protein expressed by 
macrophages and a marker of intestinal inflammation at the colon level 
(ref. calprotectina). Our serological analysis showed no particular increase 
of these two marker in our patients. Concerning the analysis of the serum 
levels of zonulin, even if the result does not show differences between 
patients and controls, must be taken into account that all patients analyzed 
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were in remission at the time of sampling. In this case, the observed data is 
in line with the result previously observed in a work conducted by Prof. 
Fasano and colleagues [190]. The data obtained from the analysis of serum 
calprotectin is consistent with that observed in the work of Floris and 
colleagues [253]. Although it is expressed in active MS lesions by 
macrophages and this expression is a good histopathological marker for 
monocyte activation, serum levels of MRP8/14 do not correlate with 
RRMS. 
To summarize the results we can conclude that: 
1) MS status significantly correlates with a defect of 1.3b and an 
excess of  1.2 EBNA-2 subtype and with newly identified 1.2 
subtype-related variants that could affect the interaction between 
EBNA-2 and cellular proteins involved in chromatin remodeling 
and gene expression of B cells.  
2) MS patients show altered values of intestinal permeability 
compared to healthy controls and low urinary concentrations of 
mannitol, that is indicative of a reduced surface of intestinal 
absorption.  
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